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RÉSUMÉ 
TDP-43 est une protéine multifonctionnelle possédant des rôles dans la 
transcription, l'épissage des pré-ARNm, la stabilité et le transport des ARNm. 
TDP-43 interagit avec d'autres hnRNP, incluant hnRNP A2, via son extrémité 
C-terminale. Plusieurs membres de la famille des hnRNP étant impliqués dans 
la réponse au stress cellulaire, alors nous avons émis l’hypothèse que TDP-43 
pouvait y participer aussi. Nos résultats démontrent que TDP-43 et hnRNP A2 
sont localisés au niveau des granules de stress, à la suite d’un stress oxydatif, 
d’un choc thermique, et lors de l’exposition à la thapsigargine. TDP-43 
contribue à la fois à l'assemblage et au maintien des granules de stress en 
réponse au stress oxydatif. TDP-43 régule aussi de façon différentielle les 
composants clés des granules de stress, notamment TIA-1 et G3BP. 
L'agrégation contrôlée de TIA-1 est perturbée en l'absence de TDP-43. En 
outre, TDP-43 régule le niveau d`ARNm de G3BP, un facteur de granule de 
stress de nucléation. La mutation associée à la sclérose latérale amyotrophique, 
TDP-43
R361S
, compromet la formation de granules de stress. Ainsi, la fonction 
cellulaire de TDP-43 s'étend au-delà de l’épissage; TDP-43 est aussi un 
composant de la réponse cellulaire au stress central et un acteur actif dans le 
stockage des ARNs. 
 
Mots clés: TDP-43, granule de stress, stress cellulaire, TIA-1, G3BP, hnRNP 
A2, sclérose latérale amyotrophique 
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ABSTRACT 
TDP-43 is a multifunctional protein with roles in transcription, pre-mRNA 
splicing, mRNA stability and transport. TDP-43 interacts with other hnRNPs, 
including hnRNP A2, via its C-terminus and several hnRNP family members 
are involved in the cellular stress response. This relationship led us to 
investigate the role of TDP-43 in cellular stress. Our results demonstrate that 
TDP-43 and hnRNP A2 are localized to stress granules, following oxidative 
stress, heat shock, and exposure to thapsigargin. TDP-43 contributes to both the 
assembly and maintenance of stress granules in response to oxidative stress and 
differentially regulates key stress granules components including TIA-1 and 
G3BP. The controlled aggregation of TIA-1 is disrupted in the absence of TDP-
43. In addition, TDP-43 regulates G3BP mRNA levels, a stress granule 
nucleating factor. A mutation associated with amyotrophic lateral sclerosis, 
TDP-43
R361S
, compromises stress granule formation. Thus, the cellular function 
of TDP-43 extends beyond splicing and places TDP-43 as a participant of the 
central cellular response to stress and an active player in RNA storage.  
 
 
Key words: TDP-43, stress granule, cellular stress, TIA-1, G3BP, hnRNP A2, 
amyotrophic lateral sclerosis 
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A. INTRODUCTION 
I. Cellular Stress  
1.1. The Cellular Stress Response 
Upon exposure to an environmental stress such as mechanical, 
chemical, heat, osmotic or oxidative, mammalian cells can activate a variety of 
different response mechanisms, which ultimately depend on the type of insult 
and severity [1]. In general, if the stress stimulus does not go beyond a certain 
threshold, the cell can adapt by activating protective responses. These responses 
are part of the Cellular Stress Response (CSR) and typically include cellular 
growth arrest and translational control mechanisms, the heat shock and 
unfolded protein responses, and the DNA damage response necessary for 
nucleic acid and chromatin repair [2]. However, if the insult exceeds cellular 
tolerance limits, cellular death pathways such as apoptosis and necrosis will be 
activated [2]. The CSR is an integral part of normal physiology and crucial for 
survival. As such, it is also highly conserved throughout evolution. 
Since stressful stimuli can impinge on normal cellular functioning, 
multiple sensors are in place to carefully monitor the environment. Sensors can 
be in the form of surface/membrane-anchored receptors such as tumor necrosis 
factor !, cysteine-rich elements in the cytoplasm, or nuclear proteins such as 
ataxia-telangiectasia mutated [3]. When a threat is detected, a cascade of signals 
is initiated typically through the activation of secondary intracellular 
messengers such as stress specific kinases. These kinases phosphorylate 
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substrates, which in turn trigger a succession of down-stream molecules [4]. For 
example, heat shock activates pathways involving stress-activated protein 
kinase p38, and leads to the phosphorylation of the Heat Shock Protein (HSP) 
27 [5, 6]. Phosphorylation of HSP27 activates a protective function either as a 
chaperone or as an inhibitor of apoptotic processes [7-9]. In the case of osmotic 
shock, activation of the stress-activated Jun NH2-terminal kinase is triggered by 
the activation of the receptors for epidermal growth factor and tumor necrosis 
factor [10].  During oxidative stress, sensing is achieved via apoptosis signal-
regulating kinase-1, a mitogen-activated protein kinase kinase kinase that can 
activate other mitogen-activated protein kinases such as p38 or Jun NH2-
terminal kinase [11]. These pathways exert their phenotypic influence through 
the modulation of transcription factors, which ultimately dictate how a cell 
responds to the insult by altering gene expression [1, 12]. 
The transcriptional regulation of gene expression can be induced by 
signaling pathways that implement changes in chromatin metabolism, followed 
by changes in the activities of transcription factors [13]. In addition, eukaryotes 
have developed a more complex system of gene regulation by the introduction 
of posttranscriptional regulation. Such regulation can occur at multiple steps 
during messenger RNA (mRNA) biogenesis and is particularly important 
during development, as there are periods when transcription is absent [14]. 
Posttranscriptional regulation is also now widely accepted as a potent 
modulator for gene expression during cellular stress, leading to a global 
repression of protein translation [14]. Translational repression during harmful 
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conditions is essential to cell survival as it permits specific stress-induced 
transcripts to receive highest translational priority. The silencing of non-
essential stress proteins is achieved through the formation of stress granules 
(SG). 
1.2. Stress Granules 
 A key element of the CSR is the re-programming of RNA metabolism in 
order to repair stress-induced damage [15]. During this process, the translation 
of “house-keeping” proteins is halted, and proteins that are essential for 
protection and survival become the focus of the translation machinery. Non-
essential mRNAs accumulate in large, dynamic, cytoplasmic foci called SGs. 
Therefore, the major role of SGs is translational repression and their formation 
correlates with decreased global translation [16]. SGs were first identified upon 
heat shock in tomato cell cultures, and have since been identified in mammalian 
cells [17, 18]. SGs are now considered to be sites of mRNA triage where one of 
three mRNA fates can ensue: re-initiation, storage, or decay [18]. SGs also 
recruit proteins involved in metabolic signaling pathways, enabling the 
assembly of SGs to influence cell metabolism and survival [19, 20].  
1.2.1. Induction of Stress Granules 
The key event leading to the formation of SGs is the phosphorylation of 
the translation initiation factor, Eukaryotic Initiation Factor 2 ! (eIF2!) [21]. 
Stress-induced phosphorylation occurs at Ser-51 of the ! subunit [22-24]. There 
are four different protein kinases known to phosphorylate eIF2!, each of which 
have a unique regulatory domain in order to respond to different stress stimuli 
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[25]. eIF2! is a heteromeric GTP-binding protein that functions in protein 
translation by forming a complex with eIF2–GTP–tRNA
Met
 and the 40S 
ribosomal subunit [25]. The phosphorylation of eIF2! during an insult reduces 
the availability of the eIF2-GTP-tRNAi
Met
 complex, leading to stalling of the 
40S ribosome on the mRNA. As a result, a pre-initiation complex is formed that 
cannot recruit the 60S ribosomal subunit to begin protein translation followed 
by polysome disassembly [26]. The stalled complexes of 40S ribosomal 
subunits along with initiation factors, and their associated mRNA transcripts, 
assemble into SGs (Fig 1.1) [25]. SG formation can also be induced by other 
stimuli in addition to eIF2! phosphorylation such as acute starvation or 
treatment with puromycin, which promote polysome disassembly [21]. 
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Figure 1.1. Model of stress granule assembly [18]. The process of SG assembly 
is initiated via the phosphorylation of eIF2!, which results in polysome 
disassembly. Stalled ribosomal complexes, initiation factors, and their 
associated mRNA transcripts, assemble into SGs. TIA-1 forms the initial SG 
aggregates onto which primary nucleating SG proteins bind, followed by 
secondary aggregation of other SG components. mRNPs sorted in SGs can 
either be stored, degraded, or prepared for re-initiation once the insult is 
removed. (Figure adapted from Anderson, P. and N. Kedersha (2008). Trends 
Biochem Sci) 
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1.2.2. TIA-1 and Stress Granule Assembly 
Following eIF2! phosphorylation, SG formation requires T-cell Internal 
Antigen-1 (TIA-1) and TIA Related Protein (TIAR) [26, 27]. TIA-1 and TIAR 
are nucleocytoplasmic RNA Binding Proteins (RBP) that are particularly 
abundant in the brain, testis and spleen [26]. TIA proteins are important for 
proper development as mice that lack TIA-1 or TIAR exhibit high embryonic 
lethality [26]. They have also been shown to participate in specific splice-site 
selection in the nucleus however, TIA proteins are best known for their role in 
SGs [26]. TIA-1 is the key nucleating protein for SG assembly where over-
expression of recombinant TIA-1, in the absence of an insult, can induce SGs 
[27]. Moreover, mouse embryonic fibroblasts lacking TIA-1 are unable to form 
bonafide SGs [28]. SGs appear to be relatively stable however, TIA-1 shuttles 
rapidly in and out of these structures. This indicates TIA-1 also likely plays a 
role in actively shuttling untranslated mRNA to SGs [26, 29]. The dynamic 
nature of TIA-1 may be an important aspect of gene regulation. By regulating 
the equilibrium between SGs and polysomes, TIA-1 can influence the 
frequency with which specific transcripts are sorted for translation [26]. The 
key role for TIA-1 in SG formation is largely attributed to its structure. 
TIA proteins are composed of three amino-terminal RNA Recognition 
Motifs (RRM) and a Carboxy (C)-terminal glutamine rich motif that is 
structurally related to prion protein [30]. The Prion Related Domain (PRD) can 
self-oligomerize forming the initial SG aggregates. TIA-1 aggregates serve as 
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scaffolds where the stalled pre-initiation complexes from the phosphorylation 
of eIF2! are routed. True SGs are then formed consisting of polyadenylated 
mRNAs, translation initiation factors, small ribosome subunits and RBPs [28]. 
Therefore, while PRD aggregation is initiated by the accumulation of stalled 
pre-initiation complexes, Gilks and colleagues have found that aggregation is 
also regulated by HSP70 [28]. By comparing the subcellular localization of 
exogenously expressed constructs for TIA-1 PRD and HSP70, the authors have 
demonstrated that in the absence of HSP70, PRD accumulates in cytoplasmic 
aggregates. Consistently, expression of HSP70 leads to the disappearance of the 
cytoplasmic aggregate and increased nuclear expression. Therefore, HSP70 is 
required to maintain TIA-1 in a nuclear, soluble form. Other factors that 
regulate TIA-1 aggregation have not yet been fully characterized; however, the 
identification of these factors is important since TIA-1 aggregation regulates 
gene expression [27]. Moreover, such factors may be important in mediating 
cell survival during stress since aggregation of TIA-1 is reversible in cells 
exposed to a sublethal stress, but irreversible in cells exposed to a lethal stress 
(e.g. 0.5 mM versus 2 mM arsenite for one hour, respectively) [27].   
The over-expression of other SG components, such as Ras GTPase-
Activating Protein-Binding Protein 1 (G3BP), is sufficient to induce SGs 
similar to TIA-1 [31]. Additional proteins, recruited as complexes, are also 
required for SG formation such as RBPs including poly(A)-binding protein 1, 
the mRNA stabilizing component HuR, and other eukaryotic initiation factors 
including eIF3, eIF4, and eIF4G [26, 29]. SGs appear 15-20 minutes following 
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exposure to stress, and are quite variable depending greatly on the types of 
Messenger Ribonucleoproteins (mRNP) present in the granules [32]. 
Furthermore, SG assembly is a transient event where once the stress is 
removed, the cell recovers with concurrent SG dispersal over 1.5-3.0 hours 
(provided that the damage does not exceed cellular thresholds) [26]. Some SG 
components, such as Staufen 1, actually promote SG disassembly [33]. SG 
disassembly is believed to correlate with the recovery of bulk protein synthesis 
such that the translation of mRNAs essential for normal cellular survival 
resumes [34]. SGs have been shown to interact with another type of RNA 
granule: Processing Bodies (PB). 
1.3 Processing Bodies 
PBs are cytoplasmic foci that function as small sites for mRNA 
degradation. There are two major mechanisms of mRNA degradation active in 
mammalian cells. One is initiated by deadenylation, followed by 3’-5’ 
exonucleolytic cleavage performed in the exosome [35]. The second is the 
removal of the 5’cap on RNA by the decapping complex, Dcp1-Dcp2, followed 
by 5’-3’ exonucleolytic cleavage of the transcript [36]. Components of the 
second pathway are found in PBs, which are essentially characterized by the 
presence of the RBP, glycine-tryptophan 182 (GW182), decapping enzymes, 
and decapping associated proteins [37]. Under physiological conditions, 
mRNAs destined for degradation can be targeted to PBs by microRNA 
(miRNA) [38]. Therefore, unlike SGs, PBs are prominent in actively 
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proliferating, unstressed cells, and are important in maintaining the balance 
between mRNA translation and decay [39]. The role of PBs in the CSR is the 
degradation of mRNAs that have been sorted and transported from SGs [35]. 
Thus, there are two subsets of PBs: one independent and motile in the 
cytoplasm, and the other stably attached to SGs [35]. Therefore, SGs and PBs 
are morphologically distinct structures and each can be assembled in the 
absence of the other. Moreover, they are functionally linked and represent a 
dynamic organization of cytoplasmic mRNPs. 
 In the cytoplasm of eukaryotic cells, several RBPs are frequently found 
in both PBs and SGs [27, 40]. In particular, several studies have indicated that 
one group of RBPs, the Heterogeneous Nuclear Ribonucleoproteins (hnRNP), 
are directly involved in cellular responses to various stresses. For example, Guil 
and colleagues have shown that activation of the p38 stress-signaling pathway 
in mammalian cells results in both the phosphorylation and cytoplasmic 
accumulation of hnRNP A1 in SGs [41]. Similarly, Quaresma and colleagues 
have demonstrated that under specific stress conditions (e.g. thapsigargin, heat 
shock and arsenite) nuclear hnRNP Q is redistributed to the cytoplasm and 
partially co-localizes to SGs and PBs [42]. hnRNP K is also a component of 
SGs and plays a role in the maintenance of cellular ATP levels during stress 
conditions [15].  
II. Heterogeneous Nuclear Ribonucleoproteins  
2.1. The hnRNP proteins: Overview 
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The hnRNP proteins are defined as RBPs that bind pre-mRNA, but are 
not stable components of other classes of RNP complexes [43]. mRNAs are 
formed from the extensive posttranscriptional regulation of primary transcripts 
from protein encoding genes [44, 45]. These transcripts, termed hnRNAs, are the 
precursors to mRNA, and hence are more commonly known as “pre-mRNA” 
[46]. As pre-mRNAs emerge from the transcription complex, and throughout the 
time in the nucleus, they are associated with proteins. These proteins include 
small nuclear ribonucleoproteins and splicing factors, however the majority 
consists of hnRNPs [43, 47]. hnRNPs associate with pre-mRNA and greatly 
influence their fate for example, by targeting specific processing factors to 
defined sites within pre-mRNA [43, 48]. These proteins, like histones, are of 
great interest because of their nuclear abundance [46]. Some hnRNPs are present 
as approximately 100 million copies per nucleus. Furthermore, in humans, at 
least 24 members of the hnRNP family, designated hnRNP A1 through hnRNP 
U, exist ranging in size from 34 to 120 kDa [46, 48, 49]. hnRNPs form 
complexes that are diverse, large and typically containing numerous dynamic 
proteins [48]. Furthermore, there is evidence that hnRNP functions, such as 
mRNA maturation and transport, are accompanied by changes in the protein 
composition of hnRNP complexes [50]. 
2.2. hnRNP Proteins are Multifunctional 
Initially, it was hypothesized that the functions of hnRNPs were mostly 
structural, such as packaging nascent pre-mRNA as a means of protection and 
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organization [43]. It was later shown that hnRNPs have more diverse subcellular 
functions. For example, hnRNP K functions as a transcriptional activator by 
interacting with cis-acting elements and RNA polymerase II transcription 
machinery [51, 52]; hnRNP E2 functions as a stabilizing factor for !-globin 
mRNA [53]; approximately 10% of all alternative splicing events are controlled 
by hnRNP A1 and H [54]; hnRNP A2 binds the SET oncoprotein, a key regulator 
of DNA replication and chromatin remodeling [55]. The relative levels of 
hnRNPs are also important and can influence alternative splicing, thus affecting 
the expression of a wide variety of genes. Additionally, hnRNPs are responsible 
for the proper functioning of mRNAs by providing information that specifies 
their nuclear export and subcellular localization. Moreover, hnRNPs can remain 
bound to mRNAs up to the ribosome, indicating roles in translation and stability 
[48]. Therefore, these multifunctional proteins are involved in virtually every 
aspect of mRNA biogenesis and gene regulation. 
2.3. hnRNP Structure Overview 
Under physiological conditions hnRNPs are primarily concentrated in 
the nucleus, however a subset of the proteins shuttle constantly between the 
nucleus and cytoplasm [50]. The structural characterization of several hnRNPs 
has revealed that shuttling is accomplished via specific amino acid sequences 
that function as Nuclear Export Signals (NES) [56]. hnRNPs that are unable to 
shuttle have specific nuclear retention signals, which prevent them from exiting 
the nucleus. Therefore, it has been suggested that shuttling hnRNPs accompany 
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mRNAs during their passage through nuclear pore complexes, while non-
shuttling hnRNPs are removed at the time of, or prior to, mRNA export [49, 
57]. Another common feature of hnRNPs is a typical modular structure in 
which one or more RBDs, generally located at the N-terminus, are associated 
with auxiliary domains [58]. Some of the most well studied hnRNP proteins are 
those that belong to the hnRNP A/B family (e.g. A1, A2, B1). In fact, these 
proteins are the most abundant hnRNP proteins, where hnRNP A1 and A2 
constitute 60% of the total protein mass of hnRNPs [59, 60]. hnRNP A/B 
proteins have two RRMs and a Glycine (Gly) rich auxiliary domain at the C-
terminus [46]. The tandem RRM-Gly structures allow the binding of other 
proteins and nucleic acids, hence their pivotal roles in mRNA processing [55]. 
Moreover, the major hnRNP A/B proteins are among the few hnRNP proteins 
that assemble into splicesomes at all major splicing stages [61]. Several hnRNP 
genes generate multiple isoforms through alternative splicing and can undergo 
posttranscriptional and posttranslational modifications [62]. These include 
phosphorylation, methylation, and glycosylation, all of which contribute to the 
complexity of this family [43]. These modifications also likely modulate 
specific interactions with other proteins and RNA [46]. Therefore, hnRNP 
proteins are an inextricable part of the pathway of gene expression from the 
transcription complex to mRNA in the cytoplasm. The contribution of these 
abundant proteins varies considerably in different cellular environments [43]. A 
new member of the hnRNP family is Trans-Activating Response Region (TAR) 
DNA-Binding Protein-43 (TDP-43). 
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III. TAR DNA-Binding Protein-43  
3.1. Protein Structure Overview 
 TDP-43 is a ubiquitously expressed cellular protein encoded by 414 
amino acids and has a molecular weight of approximately 43kDa. Structurally, 
TDP-43 is similar to hnRNPs and is most closely related to the hnRNP A/B 
family [46, 63]. It has two RRMs, RRM1 and RRM2, and a Glycine-Rich 
Domain (GRD). TDP-43 is a homodimer with four RRM domains and a 
domain arrangement similar to hnRNP A1, where RRM1 and RRM2 are 
monotetramers with four copies of the RRM in each tetrameric assembly [64]. 
The RRMs are common RNA-binding motifs with two highly conserved 
hexameric and octameric segments referred to as RNP1 and RNP2 [65]. The 
RRMs function in RNA binding and protein-protein interactions [66, 67]. 
RRM1 supplies most of the requirements for specific RNA binding however, 
RRM2 contains elements needed for correct complex formation [67]. The 
RRM2 domain shares a similar fold with other RBPs proteins except it has an 
atypical RRM-fold with an additional "-strand involved in making domain-
domain interactions [64]. The "-strand also has a role in forming a higher order 
thermal-stable complex [64]. The RRMs are flanked on either side with the N-
terminus and the glycine-rich C-terminus. 
To date, the N-terminus has not yet been fully characterized; however, 
there is evidence for a functional role in exon exclusion [68]. The GRD is 
located in the C-terminus and is involved in different aspects of splicing [66, 
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70]. Furthermore, the C-terminal region is responsible for protein-protein 
interactions including interactions with other hnRNP proteins such as hnRNP 
A2/B1, A1, C1/C2 and A3 [71]. The C-terminal tail of TDP-43 also contains 
multiple phosphorylation sites, which have a consensus sequence for casein 
kinase 1 [72]. There are also two possible Caspase-3 cleavage sites, which 
can give rise to 35 and 25kDa fragments [73]. TDP-43 contains a bipartite 
Nuclear Localization Signal (NLS) sequence, which is responsible for nuclear 
targeting as well as a leucine-rich NES [74, 75]. The structure of TDP-43 
reveals a diverse protein capable of participating in many different cellular 
functions. 
 
 
 
Figure 1.2. The structure of TDP-43 [53, 71, 81, 85, 105]. TDP-43 and has all 
of the structural features of an hnRNP protein including two highly conserved 
RRMs (RRM1 and RRM2), a nuclear localization signal, and a glycine-rich 
C-terminal. The glycine-rich C-terminal region is required for its exon 
skipping and inhibitory splicing activities. This domain also mediates protein-
protein interactions such as a direct interaction with hnRNP A2 (residues 321-
366). 
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3.2 The Importance of TDP-43: Functions  
3.2.1 Gene Regulation and RNA Processing in the Nucleus 
In the nucleus, TDP-43 is enriched in perichromatin fibrils, which are 
nuclear sites of transcription and co-transcriptional splicing, where TDP-43 
associates with nascent transcripts [76]. The first reports of TDP-43 describe its 
role as a transcription factor. Transcription factors bind DNA sequences, 
controlling the transcription of genetic information from DNA to RNA, and can 
act either positively or negatively [77]. TDP-43 was described as a 
transcriptional repressor that bound to pyrimidine sequence motifs in TAR 
DNA via its RRMs [66]. Specifically, TDP-43 repressed gene expression from 
the human immunodeficiency virus 1 long terminal repeat. In this study, TDP-
43 bound to DNA but not to RNA, despite having two RRMs. It is now 
established that the RRMs function in DNA and RNA binding as well as 
protein-protein interactions [66, 67]. RRM1 can bind to both single stranded 
(UG)n oligonucleotides and double-stranded pyrimidine rich DNA 
oligonucleotides, while RRM2 is necessary, but not sufficient for binding. 
TDP-43 also functions as a transcriptional repressor of the SP-10 gene, 
preventing its transcription in somatic tissue [78]. Reducing TDP-43 levels 
results in the de-repression and thus release of the SP-10-insulated transgene in 
a stable cell line model. Transcriptional inhibition of SP-10 by TDP-43 depends 
on the presence of the C-terminus and RRM1 [78].  
In the nucleus, TDP-43 also plays a role in splicing regulation. Splicing 
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involves the removal of introns and the joining of exons in RNA, following 
transcription [79]. It is required for correct mRNA formation. TDP-43 binds the 
TG element in human Cystic Fibrosis Transmembrane Conductance Regulator 
(CFTR) exon 9 pre-mRNA [67]. Over-expression of TDP-43 inhibits CFTR 
exon 9 splicing, while inhibition leads to an increase in exon 9 recognition. A 
second study has found that TDP-43 is responsible for CFTR exon 9 skipping 
in the presence of unfavourable (UG)mUn sequences and that the protein plays a 
dominant role over other exonic or intronic regulatory elements [69]. It is the 
N-terminus that is required for normal TDP-43 CFTR exon exclusion such that 
an N-terminal deletion mutant lacks the exon skipping activity despite having 
intact RRM domains [68]. The GRD in the C-terminus is also important for 
CFTR exon-skipping activity such that transfection of a truncated form of TDP-
43 lacking the GRD results in the loss of 90% of the exon skipping activity [60, 
70]. Moreover, the recovery of splicing following inactivation of endogenous 
TDP-43 can only be restored by Wild-Type (WT) protein expression and not by 
mutants lacking the C-terminal tail [71]. Thus, TDP-43 plays an essential role 
in inhibiting splicing via its C-terminal tail. Independently TDP-43 has been 
identified as an exon-skipping promoter during alternative splicing of  
apolipoprotein A-II and cyclin-dependent kinase 6 [80, 81]. In addition to its 
exon exclusion activity, TDP-43 is also involved in exon inclusion. TDP-43 
promotes the inclusion of exon 7 during splicing of human Survival of Motor 
Neuron (SMN) 2 pre- mRNA [82]. In support of its nuclear activities, TDP-43 
can be found in a class of nuclear structures termed TDP Bodies (TB) [83]. TB 
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link different types of nuclear bodies providing a type of network for efficient 
trafficking and sorting of different nuclear factors. This nuclear scaffold is also 
where the coupled processes of transcription and splicing occur [83]. 
Many functions performed by TDP-43 rely on protein-protein 
interactions. For example, TDP-43 interacts in vivo with SMN, a protein 
involved in the assembly of spliceosomes, sites where splicing occurs [84]. 
Additionally, TDP-43 directly binds hnRNP A2 via residues 321-366 of its C-
terminal tail [85]. This interaction provides evidence for a requirement of TDP-
43 to participate in an hnRNP complex to carry out functions such as inhibiting 
exon splicing. TDP-43 also directly interacts with Fused in 
Sarcoma/Translocated in Liposarcoma (FUS/TLS) through its C-terminal 
domain, and together TDP-43 and FUS/TLS regulate Histone Deacetylase 
(HDAC) 6 mRNA [86]. By using a global proteomics approach, Friedbaum and 
colleagues have shown that TDP-43 interacting proteins exist in two networks: 
one consists of nuclear proteins that regulate RNA splicing and nuclear RNA 
metabolism such as hnRNPs [87]. The second is a group of cytoplasmic 
proteins that regulate mRNA translation such as translation and elongation 
factors and ribosomal subunits. Therefore, TDP-43 is implicated at multiple 
levels of mRNA biogenesis including those in the cytoplasm.  
3.2.2. mRNA Biogenesis: An Extension to Cytoplasmic Functions 
Landmark studies present TDP-43 as a primarily nuclear functioning 
protein. Currently, a great deal of evidence is emerging depicting a more 
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dynamic protein involved in other aspects of mRNA biogenesis. Similar to 
other hnRNPs, TDP-43 shuttles between the nucleus and the cytoplasm, 
suggesting a role in mRNA transport [88]. Indeed, it has been demonstrated that 
TDP-43 binds human Neurofilament Light (NFL) mRNA and regulates its 
translocation between the nucleus and cytoplasm, ultimately regulating its 
translation [75]. While TDP-43 motility is dependent on the C-terminus as well 
as the NLS and NES, shuttling is also transcription dependent. Inhibition of 
transcription by the RNA polymerase II inhibitor, actinomycin D, results in 
cytoplasmic TDP-43 accumulation [88]. Therefore, continuous mRNA 
synthesis is required to signal TDP-43 import via RNA or protein-protein 
interactions. Furthermore, disruption of RNA/DNA binding ability, particularly 
by RRM1, can interfere with the correct nuclear and cellular distribution of 
TDP-43 [88]. Not surprisingly, the expression of NLS-defective mutants results 
in the cytoplasmic accumulation of TDP-43, while perturbation of the NES 
increases nuclear TDP-43 and leads to insoluble nuclear aggregates [74]. TDP-
43 also functions in mRNA transport as a component of cytoplasmic RNA 
granules [89]. Cytoplasmic granules include mRNA transport granules, SGs 
and PBs. For example, the packaging of inactive mRNAs and their transport to 
postsynaptic sites requires different RBPs [90]. In rodent hippocampal neuron 
cultures, TDP-43 resides in somatodendritic RNA granules and co-localizes 
with two other RBPs, fragile X mental retardation protein and Staufen 1, 
supporting a role for TDP-43 in RNA localization and transport [91, 92].  
In addition to transport, TDP-43 is involved in mRNA stabilization, 
  
 
 19  
sequestration, and storage. For instance, TDP-43 interacts with and stabilizes 
NFL mRNA, preventing its degradation [75]. Volkening and colleagues have 
shown that NFL mRNA stabilization is mediated by RRM1 such that TDP-43 
binding is abolished by mutations in which the RRM1 is removed, while RRM2 
is preserved [93]. Thus, supporting the essential requirement of RRM1 for RNA 
interactions, but not RRM2. TDP-43 also functions in the storage and 
stabilization of mRNA during harmful cellular conditions as a component of 
SGs. Both exogenous and endogenous TDP-43 localize to SGs following 
oxidative stress [94-96]. TDP-43 association with SGs relies on its ability to 
properly interact with RNA where cells expressing TDP-43 with a mutated 
RRM are found to contain significantly fewer SGs compared to control [89]. 
Moreover, TDP-43 co-localizes with both RNA transport and SG markers in 
motor neurons in response to sciatic axotomy [97]. This study also 
demonstrates TDP-43 redistribution from the nucleus to the cytosol and an 
increase in TDP-43 expression, indicating a more complex role for TDP-43 
during cellular injury. Together, these studies indicate TDP-43 plays a role in 
sequestering and regulating mRNA in response to cellular damage.  
TDP-43 also regulates mRNA via indirect mechanisms. In the nucleus, 
TDP-43 is found in both human and mouse microprocessor complexes, 
suggesting a role in miRNA biogenesis [15, 98]. miRNAs bind target mRNAs 
and regulate gene expression by regulating mRNA or translation levels. There 
is evidence that TDP-43 is involved in miRNA expression pathways. For 
example, removal of TDP-43 from the nucleus results in specific down 
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regulation of let-7b, a family of miRNAs important in cellular differentiation 
[89]. TDP-43 also associates with the Drosha complex, which is involved in 
primary miRNA biogenesis [98]. Therefore, the associations of TDP-43 with 
different complexes, and its localization to different types of RNA granules, 
support a role in multiple steps of RNA processing such as transport, stability 
and storage. With such diverse cellular functions, understanding the 
physiological functions of TDP-43 in different experimental models is of great 
interest.  
3.2.3. Uncovering Physiological Functions with Mouse and Fly Models 
To gain a better insight of the physiological functions of TDP-43, Wu 
and colleagues have inactivated the mouse Tardbp gene encoding TDP-43 
using a gene targeting approach [99]. In this study, homozygous Tardbp null 
mice exhibit early embryonic lethality and have defective outgrowth of the 
inner cell mass upon in vitro culturing of blastocycts. Therefore, TDP-43 is an 
essential gene for both viability and formation of the implanting blastocysts. 
Sephton and colleagues have obtained similar results demonstrating that TDP-
43 is necessary throughout embryonic development and is expressed 
predominantly in the neuroepithelium and neural progenitors during 
development [100]. In Drosophila, loss of the TDP-43 homologue, TBPD, 
affects locomotive skills with spastic, uncoordinated movements, incapacity to 
fly as well as reduced life span [101]. Interestingly, the expression of WT 
human TDP-43 in neurons also causes motor defects and reduces lifespan 
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[102]. Furthermore, homozygous null Drosophila larvae have altered 
presynaptic terminals at neuromuscular junctions. Changes include reduced 
number of axonal branches and synaptic boutons present inside muscles [102]. 
Thus, experimental models have provided insight for a role of TDP-43 in 
regulating synaptic terminals and locomotive behaviours as well as a role in 
embryonic development and life-span. Cell culture models have provided 
evidence for TDP-43 participating in cell cycle and survival. 
3.2.4. A Role in Cell Survival 
TDP-43 plays a role in cell cycle such that its depletion leads to altered 
levels of several cell proliferation factors, especially those associated with the 
retinoblastoma protein [81]. Retinoblastoma protein is essential for the control 
of the cell cycle, cellular differentiation, and maintenance of genome integrity, 
and is controlled by its phosphorylation by cyclin-dependent kinase 6. TDP-43 
depletion also leads to changes in cell cycle distribution in which there is a 
significant decrease in the number of cells in G0/G1 and an increase in S and 
G2/M cells [81]. In addition, the reduction of TDP-43 results in an increase in 
apoptotic cell death and altered nuclear morphology (e.g. membrane blebbing), 
highlighting a critical role for TDP-43 in cell survival. Many of the biological 
functions of TDP-43 are currently being unraveled. So far, researchers have 
uncovered a highly multifunctional protein with roles in nuclear and 
cytoplasmic in RNA processing, as well as an important factor in development 
and cell cycle (Fig 1.3). How mutations disrupt normal TDP-43 functions, 
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resulting in disease, is an ensuing challenge. 
 
 
 
 
 
 
 
 
 
Figure 1.3. Summary of TDP-43 functions [105]. TDP-43 is involved in several 
aspects of RNA processing including transcription, splicing and transport. More 
recently TDP-43 has been described in microprocessor complexes, suggesting a 
role in miRNA biogenesis, as well as in SGs, suggesting roles in both mRNA 
silencing and storage. (Figure is adapted from Lagier-Tourenne, C., M. 
Polymenidou, et al. (2010). Hum Mol Genet) 
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3.3. The TARDBP Gene 
3.3..1 Disease-Linked Mutations 
TDP-43 is the protein product of the TARDBP gene, which consists 
of six exons and is located at chromosome 1p36.21 [70]. TARDBP is highly 
conserved from Caenorhabditis elegans (C. elegans) to Drosophila and 
mammals. It has a low rate of sequence divergence where human, mouse, 
Drosphila, and C.elegans TDP-43 are highly homologous up to the carboxyl 
boundary of the RNP-1 in RRM2 [70]. The similarity between C. elegans and 
the other three taxa is close to 55%, and 70% if only fly and mammal are 
considered. Such data suggests that TARDBP genes are likely responsible for 
the same fundamental roles in the various organisms.  
Following the identification of TDP-43 in ubiquitin positive 
inclusions (UBI) in patients with Amyotrophic Lateral Sclerosis (ALS) and 
Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions 
(FTLDU), TARDBP became a strong biological candidate gene for familial 
forms of these diseases. This has been the case for several other 
neurodegenerative diseases such as amyloid precursor protein in Alzheimer’s 
disease and !-synuclein in Parkinson’s disease [103, 104]. Mutational 
analysis of TARDBP led to the identification of the first missense mutation in 
Familial ALS (FALS): Ala-315-Thr (c.1077 G>A) within exon 6 [103]. The 
phenotype of the affected individuals with the mutation involved a slowly 
progressive lower motor neuron degeneration syndrome with respiratory 
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involvement. Since then, a total of 38 distinct mutations have been reported 
as causative for ALS, all clustered in the GRD in exon 6 except D169G, 
which is located in RRM1 [105] (Fig 1.4). Furthermore, all of the mutations 
are missense mutations except for one truncation mutation, Y374X [106]. 
Various mutations come with different proposed mechanisms of pathology. 
For example, the D169G mutation in RRM1 may abrogate its RNA binding 
while the G348C variant may increase the propensity for aggregation by 
introducing a cysteine and thus forming intermolecular bridges [107]. Many 
mutations are also predicted to increase TDP-43 phosphorylation, particularly 
those substitutions which are threonine and serine residues (e.g. R361S, 
G287S) [107]. TARDBP mutations account for approximately 4% of FALS 
and less than 1% of Sporadic ALS (SALS) [108]. FALS accounts for 
approximately 10% of all ALS patients with mutations in Superoxide 
Dismutase 1 (SOD1) being the most common of all mutations [109]. Under 
pathological conditions, TDP-43 is commonly characterized by UBIs, protein 
cleavage, phosphorylation and mislocalization (Fig 1.5). 
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Figure 1.4. Mutations in TDP-43 [105]. A total of 38 different mutations have 
currently been reported as causative for ALS. All of the mutations are clustered 
in the GRD except D169G, which is located in RRM1. (Figure is adapted from 
Lagier-Tourenne, C., M. Polymenidou, et al. (2010). Hum Mol Genet) 
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Figure 1.5. Physiological and pathological TDP4-3 [171]. Under physiological 
conditions, TDP-43 primarily resides in the nucleus with shuttling capabilities 
(a). Under pathological conditions, TDP-43 accumulates in the cytoplasm with 
a loss of nuclear TDP-43 (b). Pathological TDP-43 has been demonstrated to be 
cleaved, hyperphosphorylated and/or ubiquitinated. (Figure is adapted from 
Chen-Plotkin, A. S., V. M. Lee, et al. (2010). Nat Rev Neurol)  
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3.4. TDP-43 Pathology 
3.4.1. Ubiquitination and Phosphorylation  
TDP-43 pathology is most prominently defined by the accumulation of 
UBIs in the cytoplasm [110]. UBIs can appear as filamentous skeins or Lewy 
body-like inclusions [111]. The presence of UBIs has led some to investigate 
whether protein degradation systems, such as the unfolded protein pathway and 
autophagy-lysosomal pathway, are involved in TDP-43 pathology. Indeed, Kim 
and colleagues have shown that TDP-43 interacts with ubiquilin 1, which is a 
proteasome targeting factor [112]. Furthermore, there is evidence 
demonstrating that both TDP-43 and a toxic p25 fragment are degraded by the 
unfolded protein pathway and autophagy-lysosomal pathway [113]. For 
instance, TDP-43 levels are increased in cells treated with MG132, a 
proteasome inhibitor, and 3-methyladenine, an autophagy inhibitor. Inhibition 
of the autophagosome or proteasome also results in marked polyubiquitination 
of TDP-43, therefore implicating degradation systems [114]. However, despite 
such evidence, confocal analysis of patient anterior horn cells has demonstrated 
that cytosolic aggregates induced by the same treatment are ubiquitin negative 
[115]. Moreover, a separate report claims that TDP-43 is not a substrate for 
ubiquitination in skein-like inclusions in patients [115]. These results present 
the possibility that TDP-43 need not be ubiquitinated to be present in 
inclusions, thus presenting the uncertainty of whether defects in protein 
degradation systems are linked to disease.  
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Biochemical analysis of the detergent-insoluble UBIs extracted from 
brains of patients with ALS and FTLD-U has shown that TDP-43 in these 
inclusions is cleaved and phosphorylated [115, 116]. The involvement of 
caspase-cleaved C-Terminal Fragments (CTF) in inclusion formation has been 
investigated in mammalian cells made to express either the 35kDa or 25kDa 
TDP-43 fragments [68]. This study has demonstrated that the expression of the 
25kDa fragment forms cytoplasmic inclusions that are ubiquitinated and 
phosphorylated at S409/410. An independent group has reported that the 
caspase-generated 35kDa CTF also becomes phosphorylated at S409/410 
during conversion of the fragment into an insoluble species [118]. There are at 
least five sites on TDP-43 that are phosphorylated in patients with ALS and 
FTLD-U and immunoreactivity against pS409/410 is particularly robust [119]. 
Moreover, abnormal phosphorylation occurs near the C-terminal region. 
Immunofluorescent staining for phosphorylated TDP-43 (pTDP-43) has shown 
that pTDP-43-positive inclusions are often found in oligodendrocytes and in the 
cytoplasm of astrocytes in the frontal cortex of patients [119]. However, 
phosphorylation of TDP-43 is not required for inclusion formation and is 
considered to be a late event occurring after the deposition of the insoluble 
protein [68]. CTF formation is also not a prerequisite for aggregation since non-
cleavable full length TDP-43 is also converted to insoluble species to the same 
extent as CTFs after apoptosis induction [118]. However, caspase-cleavage is 
thought to be a prerequisite for redistribution from the nucleus to the cytosol 
[73]. It has been postulated that TDP-43 mislocalization occurs due to the 
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aberrant cleavage of TDP-43 while it shuttles between the nucleus and 
cytoplasm [120]. In support of this, the appearance of C-terminal TDP-43 
fragments by immunoblot often accompanies TDP-43 cytoplasmic 
accumulation [74].  
3.4.2. Cytoplasmic localization 
TDP-43 is primarily a nuclear protein. However, in the context of 
disease, such as ALS, it accumulates in the cytoplasm with a concurrent 
depletion of nuclear TDP-43 [122]. This event is also observed in response to 
sciatic nerve axotomy in which there is a significant reduction in nuclear TDP-
43 and an increase in the cytoplasmic pool [97]. Sato and colleagues have 
reported similar results showing a gradual decrease of nuclear TDP-43 
following ligation of the hypoglossal nerves [121]. The decrease in TDP-43 is 
not attributed to an inhibition of transcription since TDP-43 mRNA levels 
remain unchanged. In cell culture models, cytoplasmic localization of TDP-43 
increases the risk of cell death two- to three-fold, regardless of whether neurons 
express WT or mutant TDP-43 [122]. Moreover, the amount of cytoplasmic 
TDP-43 in a cell is a strong predictor of cell death. However, cytoplasmic 
mislocalization is significantly more frequent in neurons expressing mutant 
TDP-43 then WT [122]. Interestingly, the A315T mutant is able to specifically 
induce mislocalization of TDP-43 from the nucleus to the cytoplasm [122]. In a 
model of TDP-43 proteinopathy in rat primary cortical neurons (expressing WT 
or TDP-43 bearing mutations) the authors provide evidence that mutant TDP-
  
 
 30  
43 forms ubiquitinated and detergent-resistant cytoplasmic inclusions [122]. 
Furthermore, Winton and colleagues have shown that disturbance of 
endogenous TDP-43, by mutations in the NLS or NES, can also result in the 
formation of aggregates in the cytoplasm and nucleus [74]. Such evidence 
suggests that the trafficking of TDP-43 is delicately balanced and perturbations 
of this can be a trigger for aggregation.  
To assess the factors that initiate the sequestration of TDP-43 to the 
cytoplasm, Johnson and colleagues have developed a TDP-43 proteinopathy 
model in yeast [123]. In this model, over-expression of human TDP-43 has led 
to cytoplasmic aggregation and cellular toxicity. Moreover, an experiment 
using truncated TDP-43 mutants has demonstrated that sequences within the N-
terminus are necessary to direct nuclear localization, while the C-terminus with 
an intact RRM region is required for cytoplasmic aggregation [123]. The C-
terminal region with the entire RRM2 domain is necessary for toxicity [123]. In 
a similar yeast model, several TDP-43 mutants have an increased number of 
cytoplasmic aggregates, accelerated aggregation (as determined by the extent of 
turbidity or sedimentation over time) and enhanced toxicity compared to WT 
TDP-43 [124].  
There is some debate regarding the toxicity of cytoplasmic aggregates. 
For instance, inclusion formation has been reported to enhance cellular toxicity 
[74, 123]. However, cytoplasmic aggregates have been reported in small 
atrophic neurons as well as large, otherwise healthy, neurons in humans [74, 
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123, 125]. Furthermore, inclusion formation is not required for mutant TDP-43 
toxicity as soluble forms of the protein have a neurotoxic effect that is 
independent of inclusion formation [122]. Similarly, in mice expressing a 
mutant form of TDP-43, cytoplasmic aggregates are not seen suggesting they 
are not necessary for TDP-43 induced neurodegeneration [126]. However, 
despite evidence opposing the cytotoxicity of TDP-43 aggregates, it is possible 
that their formation simply enhances TDP-43 mediated neurodegeneration. 
Therefore, the mechanism(s) of TDP-43 toxicity continues to be a matter of 
intense investigation. Insight into the role of TDP-43 under pathological 
conditions is required in order to understand neurodegenerative proteinopathies. 
3.4.3. TDP-43 Pathology in FTLDU and ALS 
TDP-43 pathology underlies major forms of sporadic and familial FTLD 
and ALS, and together the diseases are now referred to as TDP-43 
proteinopathies [111, 127]. Linking these two disorders is based on their shared 
accumulation of ubiquitin-positive cellular inclusions and the overlap in 
symptoms. FTLD is the second most common form of dementia after 
Alzheimer’s disease, with a prevalence ranging from 3.5 to 25.4 per 100 000 
[128, 129]. Clinically it is defined by behavioural and/or language dysfunction, 
and reflects the prominent frontal and temporal atrophy associated with 
neuronal loss and gliosis [111, 120]. TDP-43 pathology is found throughout the 
central nervous system however, not all FTLD-U cases show TDP-43 
pathology [120, 127]. In ALS, TDP-43 inclusions are observed in the majority 
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of cases, except in those cases resulting from mutations in the SOD1 gene [131, 
132]. Thus, TDP-43 pathology can be seen in SALS and non-SOD1-FALS, but 
not SOD1-FALS [133]. TDP-43 mutations in the TARDBP gene in ALS 
patients have provided a direct-link between TDP-43 abnormalities and 
neurodegeneration. 
3.4.4. ALS 
ALS is a late-onset and typically fatal neurodegenerative disease [134]. 
Approximately 90% of ALS cases are sporadic and the remaining 10% familial 
with a clear genetic link. The disease is characterized by the premature loss of 
upper and lower motor neurons resulting in progressive weakness, muscular 
wasting and spasticity leading to paralysis and death within three to five years 
[135]. The etiology is unknown and there are currently no effective treatments. 
It is widely accepted that multiple aberrant biological processes, such as 
enhanced oxidative injury, mitochondrial dysfunction, excitoxicity, and 
proteasome inhibition, result in motor neuron death in ALS [136-149]. Non-
neuronal cells such as microglia and astrocytes are also involved in the disease 
process [150, 151] (Fig 1.6). A new emerging theme in ALS pathology is 
aberrant RNA processing. In support of this, five RNA processing genes have 
now been linked to ALS in addition to TDP-43 including angiogenin, 
Elongatoprotein 3, senataxin, FUS/TLS and SMN [152]. Therefore, dysfunction 
in RNA processing may be a central feature in the pathology and development 
of ALS. 
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Figure 1.6. Proposed disease mechanisms in ALS [140]. Motor neuron death in 
ALS is believed to be the result of a number of aberrant processes, some of 
which include: excitotoxicity which results primarily from a failure to remove 
glutamate from synapses; proteasome inhibition due to the over accumulation 
of ubiquitinated misfolded protein aggregates; mitochondrial dysfunction which 
is mediated by mutant SOD1 deposition on the mitochondrial membrane; and 
oxidative damage due to excessive superoxide production from microglia or 
astrocytes. (Figure adapted from Ilieva, H., M. Polymenidou, et al. (2009). J 
Cell Biol) 
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IV. Aim of Study 
RNA processing is a complex and tightly regulated pathway. 
Disturbances in TDP-43, a protein involved in many different aspects of RNA 
metabolism, can lead to a number of disrupted processes such as transcriptional 
activation, pre-mRNA splicing, mRNA stabilization, and mRNA transport, all 
of which are coupled to the CSR. Therefore, since RNA regulation is critical for 
survival during cellular stress, a great deal of research is currently being 
conducted on impaired CSRs in neurodegenerative diseases.  In order to fully 
elucidate the role of TDP-43 in disease, one must have a clear understanding of 
its normal biological functions, which remain largely unknown. It is well 
established that TDP-43 localizes to SGs with oxidative stress, however its role 
in SGs remains unknown. We hypothesize that TDP-43 participates in the CSR. 
Therefore, our study aims to define the role of TDP-43 in the CSR in relation to 
SGs and whether ALS-linked mutations alter this role.  
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B. METHODS 
1. Cell Culture 
HeLa and patient lymphoblast cell lines were grown in DMEM and 
IMDM, respectively, supplemented with 10% fetal bovine serum (FBS) and 1% 
streptomycin/penicillin/glutamate.  
2. Stress Conditions 
Cells were treated with various stresses including 0.5 mM sodium 
arsenite (30 min, 37ºC; Sigma), heat shock (30 minutes, 43ºC), and 1µM 
thapsigargin (50 min, 37ºC; Sigma).  
3. siRNA Transfection 
Cells were grown in media (without antibiotics) for 24 hr to a 
confluency of approximately 30-50% on the day of transfection. For a 6-well 
plate (growth area per well: 9,6 cm"), 5 #l of Lipofectamine 2000 (Invitrogen) 
was diluted in 250 #l of Opti-MEM1 media (Invitrogen)  and incubated for 5 
min at Room Temperature (RT). Separately, 125 pmol of either Control or 
TDP-43 siRNA (Invitrogen) was diluted in 250 #l of Opti-MEM1. The two 
dilutions were combined, mixed gently, and incubated for 20 min at RT. The 
growth media on the cells was replaced with 2 ml of Opti-MEM and 500 #l of 
the transfection mix was added. The transfection mix was incubated with cells 
for 5 hr at 37°C, and subsequently replaced by fresh growth media. Cells were 
incubated for 72 hours at 37°C before harvesting. 
Control siRNA sequence: 5’-AAUUCCAGUUAUUGUAUAUAUUCAG-3’  
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TDP-43 siRNA sequence: 5’-AAGCAAAGCCAAGAUGAGCCUUUGA-3’ 
4. Cell Harvesting and Immunoblot 
The growth media was collected in a 15 ml conical. 1 ml of cold PBS 
was added to cells which were then scraped with cell scrapers. The cells were 
transferred to the 15 ml conical containing the media, followed by 
centrifugation at 16800 g, 5 min, RT. The supernatant was aspirated. The pellet 
was resuspended in 1 ml of cold PBS, transferred to 1.5 ml tube and centrifuged 
900 g, 5 min, 4˚C. The supernatant was aspirated and the pellet was 
resuspended in x #l (volume varied between 30 #l -60 #l depending on the size 
of pellet) of RIPA lysis buffer (150mM NaCl, 50mM Tris pH 7.4, 1% Triton X-
100, 0.1% SDS, 1% sodium deoxycholate). The tube was centrifuged 16200 g, 
5 min, 4˚C. The supernatant was separated from the pellet and stored at -20˚C. 
For fractionation of soluble and insoluble components, cells lysed in RIPA 
buffer were passed through a 25G syringe 6 times and centrifuged at maximum 
speed. Supernatants (soluble) were recovered and pellets (insoluble) were 
resuspended directly in 1x Laemmli sample buffer. Equal volumes of each 
fraction were separated by SDS-PAGE. The following antibodies were used in 
immunoblotting: rabbit anti-TDP-43 (1:5000; Proteintech), goat anti-TIA-1 
(1:500; Santa Cruz), goat anti-TIAR (1:200; Santa Cruz, mouse anti-G3BP 
(1:600; BD Biosciences), rabbit anti-eIF2! (1:1000; Cell Signaling), rabbit anti-
Phospho eIF2! (1:1000; Cell Signaling), and mouse anti-actin (1:400 000; MP 
Biomedicals). Blots were visualized with peroxidase-conjugated secondary 
antibodies and ECL Western Blotting Substrate (Thermo Scientific). 
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Densitometry was performed with ImageJ. 
5. Protein Concentration: BCA Assay  
A standard curve was prepared in cuvettes as follows: 
 
Standards 
(#g/ml) 
0 1 2 4 6 8 10 12 
BSA (2#g/#l ) 0 0.5 1 2 3 4 5 6 
ddH2O 50 49.5 49 48 47 46 45 44 
Table 1.1. Standard Curve 
 
1 #l of protein was added to the cuvette containing 49 #l of ddH2O in 
duplicates. BCA Reagent A was mixed with Reagent B (Thermo Scientific) in a 
ratio of 50:1. 1 ml of Reagent A/B was added mix to each cuvette with the 
protein. The mixes were incubated at 37˚C for 30 min. Protein concentrations 
were determined via spectrophotometry at 562 nm. 
6. Immunofluorescence and Antibodies  
Cells grown on coverslips were fixed in 1% formaldehyde (FA) in PBS 
for 20 min, washed with PBS and subsequently permeabilized with 0.1% 
Triton-X100 in PBS for 15 min. Coverslips were blocked with 0.1% BSA in 
PBS for 30 min and incubated with primary antibodies diluted in blocking 
buffer for 1 hr at RT. Coverslips were subsequently washed once with 0.1% 
Triton-X100 in PBS for 5 min and twice with 0.1% BSA in PBS for 5 min. 
Labeling was visualized with the fluorescently conjugated secondary antibodies 
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diluted in blocking buffer. Coverslips were them washed as before, and 
mounted with ProLong Antifade reagent (Invitrogen). Images were collected on 
a Leica SP5 confocal microscope. Primary antibodies consisted of TDP-43 
(1:300; Proteintech), TIA-1 (1:100; Santa Cruz), hnRNP A2 (1:100; Abnova), 
G3BP (1:400; BD Biosciences) and GW182 (1:50; M. Fritzler). Secondary 
antibodies consisted of donkey anti-rabbit Texas Red (Jackson 
Immunochemicals), donkey anti-goat Alexa 488 (Invitrogen), and donkey anti-
goat 633 (Invitrogen).  
7. Lymphoblastoid Immunofluroescence 
100 #l of cells (in suspension, grown in 25 ml flasks) were transferred 
into cytospin chambers which were mounted on Superfrost charged slides 
(Thermo Scientific). Chambers were centrifuged at 7000 RPM, 4 min, RT. The 
excess media was aspirated and the apparatus dissembled. Slides were left to 
dry and outlined with a hydrophobic pen. The cells were fixed with 1% FA for 
20 min, RT. Cells were then washed with 50 mM NH4Cl for 15 min and 
permeabilized with PBS/0.2%tx100 for 10 min. Following one wash with PBS, 
cells were blocked with PBS/0.1%tx100/5%BSA for 1hr, RT. The primary 
antibody, diluted in PBS/0.1%tx100, was then added and incubated for 1hr, RT. 
The slides were washed 3 times with PBS/0.1%tx100 and the secondary 
antibody, diluted in PBS/0.1%tx100, was then added and incubated for 1 hr, at 
RT. Slides were washed 3 times PBS/0.1%tx for 10 min and mounted with Pro 
Long Antifade Reagent (Invitrogen). 
8. Stress Granule Formation and Recovery 
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Cells were transfected with either Control or TDP-43 siRNA as 
described in Methods 3. 72 hr post-transfection, 0.5 mM SA was added to cells 
and coverslips were collected at the following time points after the addition of 
SA for “Stress Granule Formation”: 0, 10, 15, 20, 30 min. 
For “Stress Recovery”, 0.5 mM SA was added to cells for 30 min at 37˚C. The 
media was then replaced with fresh growth media and coverslips were collected 
at the following time points: untreated, 0 min, 15 min, 30 min, 1hr, 2 hr, 4 hr. 
Coverslips were fixed and stained as described in Methods 5.  
Slides were imaged at 63x via confocal microscopy. Four fields were imaged 
for a minimum of 100 cells per condition. Imaging settings were kept constant 
between each condition. SG-positive cells were defined as cells with at least 2 
SGs. The total number of SG-positive cells was compared for siTDP-43 and 
siControl.  
9. RNA Extraction  
RNA was extracted with RNAeasy kit (Qiagen). Specifically, cells were 
collected in 1 ml of trypsin (Invitrogen) and centrifuged at 9600 g, 5 min, RT. 
The media was aspirated and the pellet was resuspended in 350 #l RLT and 
transferred to 1.5 ml tube. Cells were then homogenized with 1 cc syringe 
equipped with a 25G needle and 1 volume of 70% ethanol was added. 700 #l of 
was added to RNeasy spin column and centrifuged 9600 g, 15 sec, RT. The 
flow through was discarded and 350 #l RW1 was added and centrifuged 9600 
g, 15 sec, RT. The flow through was discarded and 80 #l of DNase I mix was 
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added to the column (consisting of 10 #l  DNase I in 70 #l  RDD). The mix was 
centrifuged 9600 g, 15 sec, RT and 350 #l RW1 was added. The tubes were 
centrifuged 9600 g, 15 sec, RT, and the flow through was discarded.  Twice, 
500 #l of RPE was added to the column and centrifuged 9600 g, 15 sec, RT. 
The flow through was discarded and using a new collection tube, the columns 
were centrifuged  9600 g, 1 min, RT. 30 #l  of RNase free water was then 
added and centrifuged 9600 g, 1 min, RT. The eluate was added to column 
again and centrifuged 9600 g, 1min, RT. The resulting eluate was RNA. RNA 
was stored at -80˚C and concentrations were determined via  spectrophotometry 
at 260/280 nm. 
10.Reverse Transcription and cDNA Synthesis 
Reverse Transcription was performed with QuantiTect (Qiagen). 
RNA was thawed on ice. The following mix was prepared for each sample 
on ice: 2 #l gDNA wipeout buffer, x #l RNA (500 ng),  x #l ddH2O (total 
volume=14 #l). Tubes were heated at 42ºC for 2 min, then iced immediately. 
The following mix was added directly to the tubes:1#l reverse transcriptase 
(RT), 4 #l 5x RT buffer, 1 #l RT primer mix (total volume=20 #l). Tubes were 
heated at 42ºC, 30 min followed by 95ºC, 3mins, then placed on ice. cDNA was 
stored at -20ºC. cDNA was processed for qPCR with SybrGreen (Biorad). 
The following primer sets were used: $-actin exon 5 F: 5’-
CGTTGGCATCCACGAAACTA-3’; $-actin exon 6 R: 5’-
AGTACTTGCGCTCAGGAGGA-3’; TIA-1 exon 12 F: 5’-
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CATGGAACCAGCAAGGATTT-3’; TIA-1 exon 13 R: 5’-
CACTCCCTGTAGCCTCAAGC-3’; TIAR exon 11 F: 5’-
GCCAATGGAGCCAAGTGTAT-3’; TIAR intron 12 R: 5’-
CATATGCGGCTTGGTTAGGA-3’; G3BP exon 11 F: 5’-
TAATCGCCTTCGGGGACCTG-3’; G3BP exon 11 R: 5’-
AAGCCCCCTTCCCACTCCAA-3’; HuR exon 4/5 junction: 5’-
CGCAGAGATTCAGGTTCTCC-3’; and HuR exon 5 R: 5’-
CCAAACCCTTTGCACTTGTT-3’. 
 
RT-PCR conditions: 
Reagent Volume (!l ) 
DNA 1 
Forward Primer (10 uM) 1.25 
Reverse Primer (10 uM) 1.25 
dNTPs (10 uM) 0.5 
10x PCR buffer * 2.5 
TAQ * 0.5 
ddH2O 18 
*Purchased from New England Biolabs 
Table 1.2. RT-PCR Conditions 
 
12. Quantification of SG Size 
The area of 10 SGs randomly selected in at least ten cells per condition was 
manually measured with ImageJ. The average SG size of at least 100 SGs in ten 
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cells is presented.. SGs measured ranged in size from 0.75um
2
-5 um
2
. 
13. Statistical Analysis 
Data was analyzed by Student t-test or one-way ANOVA, where 
appropriate. Significance was achieved with a P-value of <0.05. Error bars 
represent standard error of the mean (SEM). 
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ABSTRACT 
TDP-43 is a multifunctional protein with roles in transcription, pre-mRNA 
splicing, mRNA stability and transport. TDP-43 interacts with other hnRNPs, 
including hnRNP A2, via its C-terminus and several hnRNP family members 
are involved in the cellular stress response. This relationship led us to 
investigate the role of TDP-43 in cellular stress. Our results demonstrate that 
TDP-43 and hnRNP A2 are localized to stress granules, following oxidative 
stress, heat shock, and exposure to thapsigargin. TDP-43 contributes to both the 
assembly and maintenance of stress granules in response to oxidative stress and 
differentially regulates key stress granules components including TIA-1 and 
G3BP. The controlled aggregation of TIA-1 is disrupted in the absence of TDP-
43. In addition, TDP-43 regulates G3BP mRNA levels, a stress granule 
nucleating factor. The disease-associated mutation TDP-43
R361S
 compromises 
stress granule formation. Thus, the cellular function of TDP-43 extends beyond 
splicing and places TDP-43 as a participant of in the central cellular response to 
stress and an active player in RNA storage. 
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INTRODUCTION 
TDP-43 was first described in the transcriptional regulation of the HIV-1 
genome where it was found to bind pyrimidine-rich sequence motifs in TAR 
DNA (1). In addition to this initially described role, TDP-43 is now known to 
be involved in several aspects of RNA metabolism including transcription, 
alternative splicing, pre-mRNA stability and mRNA transport (2-4). TDP-43 is 
composed of 414 amino acids and has all of the structural features characteristic 
of a heterogeneous nuclear ribonucleoprotein (hnRNP) including two highly 
conserved RNA recognition motifs (RRM1 and RRM2), a nuclear localization 
signal, and a glycine-rich C-terminal tail (5,6). The glycine-rich C-terminal 
region is required for its exon skipping and inhibitory splicing activities and as 
with other hnRNPs, this domain mediates protein-protein interactions (7). 
Indeed, a portion of this region (residues 321-366) mediates a direct interaction 
between TDP-43 and hnRNP A2 (2). Protein-protein interactions between 
hnRNPs are suspected to contribute to RNA-protein complex formation as well 
as direct RNA-protein interaction between hnRNPs and mRNAs (8). 
In human cells, hnRNPs are concentrated in the nucleus in 
physiologically normal conditions. However, a subset (ex. hnRNP A1, K and 
Q) continuously shuttle between the nucleus and cytoplasm (9). hnRNPs are 
involved in the extensive processing of pre-mRNAs in the nucleus, which are 
subsequently transported to the cytoplasm. Several studies have hnRNP, are 
directly involved in cellular responses to various stresses. For example, Guil 
and colleagues (2006) have shown that activation of the p38 stress-signaling 
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pathway in mammalian cells results in both the phosphorylation and 
cytoplasmic accumulation of hnRNP A1 in SGs (10). Similarly, Quaresma and 
colleagues (2009) have demonstrated that under specific stress conditions (e.g. 
thapsigargin, heat shock and arsenite) nuclear hnRNP Q is redistributed to the 
cytoplasm and partially co-localizes to SGs and PBs (11).  
Depending on the type of cellular stress encountered, a variety of signaling 
pathways can be activated which ultimately modulate gene expression patterns 
either transcriptionally or post-transcriptionally (12). RNA binding proteins 
(RBP) play a major role in post-transcriptional regulation during stress yielding 
global repression of protein translation (12,13). This is facilitated by the 
formation of SGs which are cytoplasmic domains housing translationally 
arrested mRNAs (10). SGs are also now considered to be dynamic triage 
centers that sort mRNA for storage, decay, or re-initiation during stressful 
conditions (14,15). The assembly of SGs can be induced by a variety of stimuli 
including heat shock, hypoxia, osmotic and oxidative stress and typically 
involves the phosphorylation of the eukaryotic initiation factor eIF2!. This 
phosphorylation event inhibits mRNA translation through depletion of the eIF2-
GTP-tRNA-met ternary complex thus permitting the RNA-binding protein 
TIA-1 to bind the 48S complex instead of the ternary complex. This promotes 
polysome disassembly and the consequent recruitment of mRNAs to SGs (10). 
SGs gradually disperse once the stress is removed (12). Since TDP-43 shares so 
many features with other hnRNPs, it is reasonable to suspect it may also play a 
role in cellular stress responses.  
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We report here that TDP-43 and its binding partner hnRNP A2 are 
components of SGs arising from oxidative stress. Furthermore, TDP-43 down-
regulation influences the stoichiometry of other SG protein components 
including TIA-1, TIAR, and G3BP. Moreover, TDP-43 contributes to SG 
formation and maintenance. In patient lymphoblastoid cells, at least one ALS-
causing mutation in TDP-43 impacts SG formation. Our data suggests that not 
all TDP-43 mutations have the same mechanism and clearly define an active 
role for TDP-43 in the cellular response to oxidative stress. 
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RESULTS 
Endogenous TDP-43 is localized to stress granules. Various types of insults are 
known to affect the expression and localization of several hnRNPs with some 
localizing to SGs (10,14). Since TDP-43 is a bona fide hnRNP family member, 
we investigated whether cellular stress could also affect endogenous TDP-43. 
To address this, HeLa cells were exposed to three well-established cellular 
stress conditions: sodium arsenite (SA), heat shock (HS), and thapsigargin 
(THAP). SA treatment is a well-characterized model of oxidative stress, while 
THAP induces ER stress via calcium pump dysregulation. Endogenous TDP-43 
was localized to distinct cytoplasmic puncta upon SA, HS, and THAP treatment 
whereas TDP-43 remained largely in the nucleus of untreated cells (Fig. 1A). 
Double-labeling demonstrates that these TDP-43 puncta co-localize with the 
well-described SG marker, TIA-1 in SA, HS, and THAP treated cells (Fig. 1A). 
Biochemically, the formation of SGs is marked by the enhanced protein 
insolubility of SG proteins (and consequent depletion of the soluble pool) such 
as is described for TIA-1 (17,18). Indeed, soluble TDP-43 protein levels were 
decreased in HS and SA treated cells (37% and 56%, respectively) compared to 
untreated cells and there was a significant reciprocal increase in TDP-43 in the 
insoluble fractions (Fig. 1B). However, THAP treatment does not yield similar 
changes in protein solubility.  
To determine if TDP-43 is also a resident of other RNA granules, such as 
Processing Bodies (PBs), we double-labeled SA-stressed HeLa cells for the PB 
marker, GW182. TDP-43 was not robustly co-localized with GW182-labeled 
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PBs (Fig. 1C) but rather was often located in close proximity to PBs. This is 
consistent with published data demonstrating the close juxtapositioning of SGs 
and PBs (19). Thus, TDP-43 is a resident of SGs but not PBs following acute 
exposure to certain stressful stimuli, in agreement with recent reports (20,21). 
A cell’s encounter with external stress is marked by the global repression of 
protein translation and this is reflected by the phosphorylation of the eukaryotic 
translation initiation factor 2 alpha (eIF2!) (12). Since we observed eIF2! 
phosphorylation most robustly in SA treated samples, we focused on SA as a 
stress paradigm for subsequent experiments (Fig. 1D).  
TDP-43 impacts SG assembly and disassembly. Several cellular proteins are 
required for SG assembly and their reduction is associated with a muted SG 
response (17,22-24). SGs are dynamic entities such that oxidative stress induces 
TIA-1 to redistribute from the nucleus to the cytoplasm and aggregate to form 
SGs (12). This process occurs over approximately 30 minutes (17). Once the 
stress is removed, SGs continue to aggregate and increase in size for 
approximately 1-2 hours before gradually resolving. Typically, SGs are 
completely resolved within 4 hours of SA treatment. To determine if TDP-43 
might impact SG dynamics, we assessed the kinetics of SG formation and 
resolution via indirect immunofluorescent labeling for TIA-1 in cells depleted 
of TDP-43 via siRNA and then exposed to SA. The number of cells exhibiting 
SGs was determined at 0, 15, 20 and 30 minutes during SA (“stress”) exposure. 
Compared to control siRNA, siRNA directed to exon 1 of TDP-43 was very 
effective in reducing endogenous TDP-43 expression (84%, n=5; Fig. 2A). We 
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observed that the assembly of TIA-1 labeled SGs was delayed in cells depleted 
of TDP-43 compared to cells treated with control siRNA (Fig. 2B). In 
particular, we noted a modest but significant reduction in the number of cells 
with successful SG formation at 30 minutes following SA exposure (97% vs. 
81%, p=0.03) as well as a marked change in SG size which will be discussed 
below.  
To assess the impact of TDP-43 on SG resolution, we also assessed SG 
labeling at various time points following the removal of SA (“release”). After 
30 minutes of oxidative stress, TIA-1 labeled SGs are detectable in 97% of 
control siRNA cells, and are small, numerous and clearly defined (Fig. 2C, left 
panel). Within 90 minutes, the number of SG positive cells continues to be 
>94% however, SGs become larger and fewer in number due to the fusion of 
several smaller SGs and acquire a well defined, compact shape (12). SGs then 
begin to gradually resolve and by 270 minutes (4 hours release) will few if any 
cells still containing SGs (Fig. 2C). Our observations of this process are 
consistent with the published kinetics of SG disassembly (12). In TDP-43 
depleted cells, there is a striking difference in SG dynamics such that TDP-43 
depleted cells are slower to form morphologically distinct SGs compared to 
control (Fig. 2C, right panel). This difference is most obvious in the first 30 
minutes after SA treatment as the number of SG-positive cells continues to be 
reduced at 45 and 60 minutes post stress, compared to control siRNA cells (Fig. 
2B). Furthermore, SGs in TDP-43 depleted cells have more diffuse TIA-1 
labeling (ie. TIA-1 is not completely localized as distinct foci) and SGs appear 
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smaller with a less-defined and more irregular morphology. Thus, SGs in TDP-
43 depleted cells are visibly different compared to the prominent SGs formed in 
control siRNA cells following the same stress stimulus (Fig. 2C). 
Quantification of SG size reveals that average SG size is reduced 43% in TDP-
43 depleted cells compared to controls (0.83 ± 0.08 vs. 1.46 ± 0.12 µm
2
; 
p=0.0002) (Fig. 2D).  
Our data indicates that the lag in SG assembly in siTDP-43 cells is 
overcome by 90 minutes, such that the number of cells with SGs is equivalent 
in both TDP-43 and control siRNA cells and SG size and morphology are 
comparable. However, at 150 minutes, only 1% of TDP-43 siRNA cells have 
obvious SGs, while SGs persist in 31% of control siRNA cells (p=0.04) (Fig. 
2C). Therefore, depletion of TDP-43 results in a lag in SG assembly such that 
SG nucleation and secondary aggregation seem to be delayed. Furthermore, 
SGs in TDP-43 depleted cells are smaller and only later attain normal-
appearing SGs. However, these SGs are not sustained and quickly resolve. 
Thus, endogenous TDP-43 contributes to both the establishment of SGs and is 
required to maintain SGs. 
It has been reported that exogenous expression of some SG components is 
sufficient to nucleate SGs (17,23). Since our earlier data suggests a role for 
TDP-43 in SG nucleation, we assessed SG formation in cells transiently 
transfected with GFP-tagged full-length TDP-43. Overexpression of TDP-43 
was not sufficient to nucleate SGs but does itself correctly localize to SGs 
following SA treatment (data not shown). 
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TDP-43 differentially regulates SG nucleating proteins. TIA-1 and G3BP 
are both considered as primary nucleators of SGs (25). We hypothesized that 
TDP-43 may regulate the levels of these proteins, either at the transcriptional or 
post-transcriptional level. Immunblot analysis of steady-state levels of key SG 
proteins, including TIA-1, TIAR, and G3BP revealed that TIA-1 was up-
regulated 130% (p=0.03) in TDP-43 siRNA cells, while G3BP was down-
regulated 79% (p=0.05; Fig. 3A). At the transcriptional level, qPCR with gene-
specific primers revealed even more marked alterations were seen in steady 
state mRNA levels. Specifically, we noted a 2.6-fold increase (p=0.01) for TIA-
1, while G3BP mRNA was reduced 3-fold (p=0.007; Fig. 3B). A trend towards 
upregulation of TIAR was also noted at both the protein and mRNA level, but it 
did not reach statistical significance (p=0.059). Moreover, the effect of TDP-43 
depletion was selective for TIA-1 and G3BP since another SG component HuR 
remained unchanged (Fig. 3B). Thus, TDP-43 differentially regulates the 
transcription of SG- nucleating proteins.  
The phosphorylation of the eukaryotic initiation factor eIF2! at serine 51 is 
an important early initiating step in SG assembly in response to oxidative stress 
(10). To determine whether eIF2! was intact in TDP-43 depleted cells, we 
immunoblotted control and TDP-43 siRNA cell lysates in the presence and 
absence of SA with an antibody specific for serine-51 phospho-eIF2!. 
Following SA treatment, we did not observe a remarkable change in phospho-
eIF2! levels in the presence or absence of TDP-43, placing TDP-43 
downstream of this step of the stress response (Fig. 3C). Moreover, in untreated 
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conditions, the depletion of TDP-43 itself did not induce phosphorylation of 
eIF2! suggesting that the removal of TDP-43 does not outright trigger an 
intracellular stress response. 
TDP-43 facilitates TIA-1 redistribution. Over-expression of TIA-1 is 
sufficient to induce SG formation (17) and TDP-43 interacts with TIA-1 (20). 
However, our data indicates diffuse TIA-1 labeling in TDP-43 depleted cells 
and slowed SG assembly but paradoxically higher TIA-1 steady state levels. 
However, it is well described that the recruitment of TIA-1 into SGs is marked 
by the redistribution of TIA-1 from soluble to insoluble compartments (17,18). 
Thus, we speculated that TDP-43 might influence TIA-1 aggregation. To this 
end, we examined TIA-1 distribution in soluble and insoluble fractions of 
control and TDP-43 depleted cells. In contrast to control siRNA cells, we 
observed a 39% increase in soluble TIA-1 when TDP-43 is reduced compared 
to cells treated with control siRNA (p=0.03; Fig. 4A) with a concomitant 
decrease in the insoluble pool. Therefore, our data suggest that TDP-43 impacts 
the compartmentalization of TIA-1.  
TDP-43 impacts G3BP SGs. Given the significant down-regulation of 
G3BP in TDP-43 siRNA cells, we investigated the ability of cells to form 
G3BP-labeled SGs immediately following SA treatment. Control siRNA cells 
treated with SA contain numerous large SGs labeled with both G3BP and TIA-
1. In contrast, when TDP-43 is reduced, there is a generally more diffuse 
labeling of G3BP and the number of cells with SGs is reduced (Fig. 4B). In 
cells which do form SGs, it appears that the number of G3BP-labeled SGs is 
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markedly reduced and these SGs are much reduced in size compared to their 
control counterparts. TIA-1 and G3BP co-localization appears to be maintained 
(Fig. 4B). 
Endogenous hnRNP A2 is a resident of SGs. TDP-43 interacts with hnRNP 
A2 (2). Thus, we investigated whether hnRNP A2 could also be a component of 
SGs. Following SA exposure, endogenous hnRNP A2 redistributed so that it 
was co-localized with TIA-1 (Fig. 5A). Moreover, triple labeling revealed that 
hnRNP A2 co-localized with TDP-43 in SGs (Fig. 5B) indicating that 
endogenous TDP-43 and hnRNP A2 are residents of the same SGs in 
conditions of oxidative stress. We hypothesized that TDP-43 may also 
influence hnRNP A2 localization. Thus, we examined the localization of 
hnRNP A2 to SGs in cells treated with TDP-43 siRNA and subjected to SA 
treatment. As before, siTDP-43 cells had fewer SGs per cell and SG size was 
decreased (Fig. 5C). hnRNP A2 labeling in the absence of TDP-43 showed few 
distinct puncta which did colocalize to TIA-1 marked SGs. However, the cells 
appeared to have an increased patchy distribution within the cytosol compared 
to control siRNA cells. Thus, TDP-43 influences hnRNP A2 localization to SGs 
(Fig. 5C). 
SG assembly is disrupted by TDP-43
R361S
 mutation. In a cellular 
overexpression model, mutant FUS/TLS has recently been described to be 
sufficient to induce SGs (26,27). Thus, we hypothesized that mutations in TDP-
43 may alter SG formation in response to oxidative stress. In order to avoid 
artifacts potentially introduced by transient overexpression of TDP-43, we took 
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advantage of patient lymphoblasts expressing physiological levels of wild type 
and two different TDP-43 mutations, TDP-43
D169G
 and TDP-43
R361S
. We 
verified that steady-state levels of TDP-43 protein were not reduced in the 
different cells (Fig. 6A). In fact, we noted a slight increase in mutant TDP-43 
protein levels such that TDP-43
D169G
 and TDP-43
R361S
 proteins accumulated to 
1.2x (p=0.04) and 1.3x (p=0.01) relative to controls cells expressing TDP-43
WT
. 
Lymphoblasts were treated with SA and SG formation was scored using TIA-1 
as a marker. In control cells expressing a non-pathogenic silent polymorphism 
(A66A), distinct SGs are robustly present in 10% of the population following 
oxidative stress (Fig. 6B). In contrast, we observed a 2-fold reduction in the 
number of cells forming SGs in cells expressing TDP-43
R361S
 mutation (p=0.01; 
Fig. 6B). Interesting, SG formation in cells expressing TDP-43D169G was 
comparable to control.  
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DISCUSSION 
Our studies indicate that TDP-43 contributes to the cellular response to 
acute stress. Specifically, endogenous TDP-43 is recruited into SGs which are 
considered to be a key element to the protective response to cellular stress. 
Moreover, our data demonstrates that TDP-43 participates in regulating SGs 
such that depletion of TDP-43 delays SG nucleation and secondary aggregation 
via the differential deregulation of key nucleating factors TIA-1 and G3BP at 
the transcriptional level. Furthermore, the number and size of TIA-1 and G3BP 
positive SGs are reduced in cells depleted of TDP-43 and subsequently treated 
with oxidative stress. TDP-43 therefore contributes positively to both SG 
assembly and their maintenance. Our use of TDP-43 siRNA demonstrates that 
formed SGs are unable to persist and that they resolve quickly in cells depleted 
of TDP-43. It is well accepted that following the removal of a stress, SGs 
disassemble, and the majority of released mRNAs are recruited back to the 
translation machinery (28). Thus, the contribution of TDP-43 to the assembly 
and disassembly of SGs offers an important mechanism by which TDP-43 may 
regulate gene expression in response to stress.  
Interestingly, TDP-43 has been reported to interact with TIA-1 and TIAR, 
both core nucleating components of SGs (20). Our study shows that TDP-43 
directly modulates the expression of TIA-1 and G3BP (and less so TIAR), 
providing a potential mechanism for the impact of TDP-43 on SG dynamics. It 
has been previously shown that the levels of SG-associated proteins 
significantly increase in the insoluble fraction during biochemical fractionation 
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of cells treated with various stresses (17,18). The efficiency with which TIA-1 
can transition between its soluble and insoluble forms is essential for SG 
assembly and disassembly. Our data demonstrate that TDP-43 can modulate 
TIA-1 redistribution, thus we speculate that the association between TDP-43 
and TIA-1 facilitates the homotypic interactions of TIA-1 (and thus modifies its 
solubilization) which are required for SG assembly and maintenance. The 
transcriptional down-regulation of G3BP by TDP-43 also yields fewer SGs. 
Thus, TDP-43 regulates SG formation via two independent mechanisms. 
TDP-43 interacts with hnRNP A2 (2). In the presence of acute oxidative 
stress, endogenous hnRNP A2 was also recruited to SGs. This is the first 
description of hnRNP A2 localization to SGs and our data indicates that it may 
be partially dependent on TDP-43. Specifically, the down-regulation of TDP-43 
yielded fewer and smaller hnRNP A2-labeled SGs. Whether this is due to the 
direct action of TDP-43 on hnRNP A2 or a consequence of slowed SG 
assembly due to TDP-43 regulation of G3BP transcription and/or TIA-1 
redistribution remains to be clarified.  
The localization of TDP-43 to SGs, the regulation of SG proteins by TDP-
43, and the delay in SG assembly and maintenance in the absence of TDP-43 
suggests a novel function for TDP-43 in acute stress. It will be interesting to 
evaluate the role of TDP-43 in chronic stress. Our observation that the TDP-
43
R361S
 mutation is hampered in its ability to form SGs is interesting and 
suggests a potentially disease-relevant mechanism. (Note, continuous life-time 
expression of a mutant protein may itself be a model of chronic stress.) In a 
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transient overexpression culture model it has previously been reported that 
TDP-43
R361S
 reduces mRNA expression of the histone deacetylase HDAC6 
(29). Separately, the down-regulation of TDP-43 results in reduced 
transcription of HDAC6 (29) (data not shown). HDAC6 has been published as 
important determinant in SG assembly (30) and TDP-43 and FUS/TLS have 
recently been reported to cooperatively regulate HDAC6 mRNA (31). In 
addition to its role in SG dynamics, HDAC6 is also involved in the removal of 
misfolded proteins and aggresome formation (32). Large cytoplasmic 
aggregates are a feature of ALS, thus deregulation of HDAC6 by TDP-43 
mutations is a very interesting target worthy of future investigation.  
In the context of ALS, mutations in TDP-43 could compromise the cellular 
stress response such that one could envision successive cycles of a weakened 
stress response leading to a maladaptive state. Successive encounters with 
oxidative stress would eventually overcome the cell’s ability to manage the 
stress, and ultimately result in cellular demise (Fig. 7). Furthermore, it remains 
possible that large pathological aggregates arise due to disrupted SG dynamics 
as has been proposed in Parkinson’s disease (33). This aspect remains to be 
tested in ALS. Importantly, we report here SG formation is not disturbed by the 
TDP-43
D169G
 mutation suggesting that it may be mechanistically independent of 
the reported C-terminal mutants. The nature of this mutation, predicted to be 
mRNA binding, remains to be demonstrated.  
We describe a mechanistic role for endogenous TDP-43 in the cellular 
stress response. Our data suggests that TDP-43 regulation of stress granule 
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pathways may be a disease relevant mechanism. Defining the relevance of this 
aspect of TDP-43 biology in motor neurons and ALS is now an ensuing 
challenge. 
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MATERIALS AND METHODS 
 Plasmids, Cell Culture and Transfection- HeLa patient lymphoblast cell 
lines were grown in DMEM and IMDM, respectively, supplemented with 10% 
fetal bovine serum (FBS) and 1% streptomycin/penicillin/glutamate. For 
transfection of small interfering RNA (siRNA), 125 pmol of custom siRNAs 
were transfected with Lipofectamine 2000 (Invitrogen), according to the 
manufacturer’s instructions. Control and TDP-43 siRNA sequences were 5’-
AAUUCCAGUUAUUGUAUAUAUUCAG-3’ and 5’-
AAGCAAAGCCAAGAUGAGCCUUUGA-3’, respectively (Invitrogen). Cells 
were transfected at 30-50% confluency. Transfection media was replaced with 
regular culture media without antibiotics after five hours. Cells were collected 
after 72 hours of siRNA treatment. 
Cells were treated with various stresses including 0.5mM sodium arsenite 
(30 minutes, 37ºC; Sigma), heat shock (30 minutes, 43ºC), and 1µM 
thapsigargin (50 minutes, 37ºC; Sigma). For stress recovery experiments, cells 
were stressed and then media was replaced, and cells were permitted to recover 
for various times prior to collection and fixation.  
Immunofluorescence and antibodies- Cells grown on coverslips were fixed 
in 1% formaldehyde (FA) in PBS and subsequently permeabilized with 0.1% 
Triton-X100 in PBS for 15 minutes. Coverslips were blocked with 0.1% BSA 
in PBS for 15 minutes and incubated with antibodies to TDP-43 (1:300; 
Proteintech), TIA-1 (1:100; Santa Cruz), hnRNP A2 (1:100; Abnova), G3BP 
(1:400; BD Biosciences) and GW182 (1:50; M. Fritzler) diluted in blocking 
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buffer for 1 hour at room temperature. Coverslips were subsequently washed 
once with 0.1% Triton-X100 in PBS and twice with 0.1% BSA in PBS. 
Labeling was visualized with the fluorescently conjugated secondary antibodies 
donkey anti-rabbit Texas Red (Jackson Immunochemicals) and donkey anti-
goat Alexa 488 (Invitrogen). Coverslips were washed as before, and mounted 
with ProLong Antifade reagent (Invitrogen). Lymphoblasts were affixed to 
Superfrost charged slides via cytospin and then subsequently fixed and labeled, 
as previously described (16). Images were collected on a Leica SP5 confocal 
microscope. 
Quantification of SG size- The area of ten SGs (ranging from 0.75um
2
-5 
um
2
), randomly selected in at least ten cells per condition was manually 
measured with ImageJ. The average SG size of at least 100 SGs in ten cells is 
presented. 
Cell lysates and immunoblot analysis- Cells were collected in ice cold PBS, 
lysed in RIPA buffer (150mM NaCl, 50mM Tris pH 7.4, 1% Triton X-100, 
0.1% SDS, 1% sodium deoxycholate), and centrifuged at 16 000xg. 
Supernatants were collected and quantified with the BCA Protein Assay Kit 
(Thermo Scientific). For fractionation of soluble and insoluble components, 
cells lysed in RIPA buffer were passed through a 25G syringe 6 times and 
centrifuged at maximum speed. Supernatants (soluble) were recovered and 
pellets (insoluble) were resuspended directly in 1x Laemmli sample buffer. 
Equal volumes of each fraction were separated by SDS-PAGE. The following 
antibodies were used in immunoblotting: rabbit anti-TDP-43 (1:5000; 
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Proteintech), goat anti-TIA-1 (1:500; Santa Cruz), goat anti-TIAR (1:200; Santa 
Cruz, mouse anti-G3BP (1:600; BD Biosciences), rabbit anti-eIF2! (1:1000; 
Cell Signaling), rabbit anti-Phospho eIF2! (1:1000; Cell Signaling), and mouse 
anti-actin (1:400 000; MP Biomedicals). Blots were visualized with peroxidase-
conjugated secondary antibodies and ECL Western Blotting Substrate (Thermo 
Scientific). Densitometry was performed with ImageJ. 
qPCR- RNA was extracted with RNAeasy kit (Qiagen) and reverse 
transcribed with QuantiTect (Qiagen). Resulting cDNA was processed for 
qPCR with SybrGreen (Biorad) according to the manufacturer’s instructions 
using the following primer sets: $-actin exon 5 F: 5’-
CGTTGGCATCCACGAAACTA-3’; $-actin exon 6 R: 5’-
AGTACTTGCGCTCAGGAGGA-3’; TIA-1 exon 12 F: 5’-
CATGGAACCAGCAAGGATTT-3’; TIA-1 exon 13 R: 5’-
CACTCCCTGTAGCCTCAAGC-3’; TIAR exon 11 F: 5’-
GCCAATGGAGCCAAGTGTAT-3’; TIAR intron 12 R: 5’-
CATATGCGGCTTGGTTAGGA-3’; G3BP exon 11 F: 5’-
TAATCGCCTTCGGGGACCTG-3’; G3BP exon 11 R: 5’-
AAGCCCCCTTCCCACTCCAA-3’; HuR exon 4/5 junction: 5’-
CGCAGAGATTCAGGTTCTCC-3’; and HuR exon 5 R: 5’-
CCAAACCCTTTGCACTTGTT-3’. 
Statistical analysis- Data was analyzed by Student t-test or one-way ANOVA, 
where appropriate. Error bars represent standard error of the mean (SEM).  
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FIGURE LEGENDS 
Figure. 1: TDP-43 is localized to stress granules. (A) HeLa cells cultured on 
coverslips were treated with 0.5mM sodium arsenite (30 mins; SA), 1 µM 
thapsigargin (50 mins; TH), and 43°C heat shock (30 mins; HS), or left as 
untreated (UN) and subsequently immunolabled for TDP-43 and the SG marker 
TIA-1. TDP-43 localization to SGs is indicated by line scans of the merged 
images showing the overlap between red and green signals. Scale bar, 10 µm. 
(B) RIPA-soluble and -insoluble extracts were prepared from stressed cells and 
then immunoblotted for TDP-43. Actin is included as a loading control. Data 
are representative of three independent experiments. (C) TDP-43 was not 
markedly co-localized with the PB marker, GW182. (D) Phosphorylation of 
eIF2! was assessed in the four stress conditions. 
 
Figure 2: TDP-43 regulates stress granule dynamics. (A) TDP-43 protein 
levels are reduced by siRNA. Values indicate TDP-43 present as determined by 
densitometry and are the average of five independent experiments. Data were 
normalized to actin. (B) SG formation and resolution were assessed in Hela 
cells transfected with control or TDP-43 siRNA for 72 hours and subsequently 
treated with SA. Coverslips were collected at 0, 15, 20, and 30 minutes after the 
addition of SA to assess formation (“Stress”). After 30 minutes the media was 
replaced and coverslips were collected at 45, 60, 90, 150 and 270 minutes after 
the addition of SA (“Release”). SGs were scored via TIA-1 labeling. Four fields 
per condition, representing at least 100 cells, were imaged and the number of 
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cells containing SGs was counted. The means of three independent experiments 
+/- SEM are plotted. *, p<0.05. (C) SG morphology in siTDP-43 or siControl 
HeLa cells treated with SA at “release” time points labeled with TIA-1. Scale 
bar, 10um. (D) SGs are smaller in cells transfected with TDP-43 siRNA. The 
average area +/- SEM is plotted at 30 minutes post-stress.  
 
Figure 3: TDP-43 regulates G3BP and TIA-1. (A) Western blot analysis of 
soluble fractions of control and TDP-43 siRNA cells indicates decreased levels 
of G3BP and increased accumulation of TIA-1 and to a lesser extent TIAR. 
Data was normalized to actin via densitometry. Data from two to three 
independent experiments are expressed as the mean fold change +/- SEM 
relative to siControl cells *, p<0.05. (B) qPCR analysis of G3BP, TIA-1, and 
TIAR. HuR remained unchanged. Data normalized to $-actin and fold change is 
plotted. *, p<0.01. (C) TDP-43 siRNA is not sufficient to induce eIF2! 
phosphorylation, and this event is not disrupted by TDP-43 depletion. 
 
Figure 4: TDP-43 alters TIA-1 solubility and reduces G3BP SG formation. 
(A) RIPA soluble and insoluble fractions from control siRNA and TDP-43 
depleted cells were analyzed via western blot for TDP-43 and TIA-1. Data is 
representative of three independent experiments. (B) Formation of G3BP SGs 
was assessed in HeLa cells transfected with control or TDP-43 siRNA for 72 
hours and subsequently treated with SA. Coverslips were collected immediately 
and labeled for TIA-1 and G3BP. 
  
 
 71  
 
Figure 5: Endogenous hnRNP A2 is localized to stress granules. HeLa cells 
cultured on coverslips were treated with 0.5mM sodium arsenite (30 mins; SA) 
or left as untreated (UN) and subsequently immunolabeled for (A) hnRNP A2 
and TIA-1 or (B) hnRNP A2, TDP-43 and TIA-1. Scale bar, 10 #m. hnRNP A2 
co-localization to SGs is quantified by line scans of the merged images showing 
the overlap between red and green (and blue) signals. Scale bar, 10 #m. (C) 
Localization of hnRNP A2 to SGs (marked with TIA-1) was assessed in HeLa 
cells transfected with control or TDP-43 siRNA for 72 hours and subsequently 
treated with SA. Coverslips were collected immediately and labeled for TIA-1 
and hnRNP A2. Scale bar, 10 #m. 
 
Figure 6: The disease-causing mutation TDP-43R361S impacts SG 
formation. (A) Immunoblot of steady-state TDP-43 protein levels in RIPA cell 
lysates from control human lymphoblasts or patients expressing the disease-
causing mutations TDP-43
D169G
 and TDP-43
R361S
. Data is representative of four 
experiments. Histogram indicates quantification via densitometry. *, p<0.05. 
(B) Control and mutant patient cells were treated with SA or left untreated 
(UN). Cells were labeled with TIA-1 and the number of SG-positive cells was 
counted from a minimum of three fields representing at least 100 cells. The 
mean +/- SEM of four independent experiments is plotted. *, p<0.05.  
 
Figure 7: Model of TDP-43 in the regulation of SGs. Reduced TDP-43 
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protein levels or TDP-43 mutations yield a reduction in G3BP and disrupt TIA-
1 aggregation. These events yield slowed and diminished SG formation and 
poor maintenance. This may increase cellular susceptibility to acute stress 
stimuli and contribute to cellular death. This could set up a feed-forward 
amplification loop resulting in a maladaptive state in motor neurons, thereby 
contributing to an increased vulnerability over time. 
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ABBREVIATIONS 
SG, stress granule 
PB, processing body 
ALS, amyotrophic lateral sclerosis 
FTD, frontotemporal dementia 
hnRNP, heterogeneous nuclear ribonucleoprotein
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D. DISCUSSION 
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TDP-43 redistribution  
In this study we define a pivotal role for TDP-43 in the CSR. The CSR 
represents an evolutionary evolved mechanism by which cells respond and 
defend against changes in their environment [154]. One of the most immediate 
responses to cellular stress is a very rapid reversible suppression of mRNA 
translation, triggered by the phosphorylation of the translation initiation factor 
eIF2!. Translationally stalled mRNAs are recruited to discrete cytoplasmic foci 
called SGs. Our results demonstrate that endogenous TDP-43 forms 
cytoplasmic puncta following exposure to oxidative stress which colocalize 
with SGs, consistent with recently published reports [94, 95]. TDP-43 also 
localizes to SGs with HS and THAP treatment. Furthermore, we show TDP-43 
redistribution with both SA and HS however, SA induces a much more robust 
stress response in our experimental model. Arsenite is a potent environmental 
toxin that contributes to human pathogenesis resulting in skin disease, cancer, 
and cardiovascular disease [25]. Arsenite also represents an oxidative stress, 
which is of particular interest in the case of TDP-43 since one of the major 
commonalities of neurodegenerative diseases is the progressive accumulation 
of damage resulting from oxidative stress in the CNS [155]. There is evidence 
of increased oxidative stress in Alzheimer’s disease, Parkinson’s disease, ALS 
and FTLD. In our study, TDP-43 protein expression is decreased in RIPA-
soluble fractions and increased in RIPA-insoluble fractions. RIPA insoluble 
cellular fractions typically consist of chromatin and/or nuclear matrix 
components of structure bound portions of the nucleus [88]. TDP-43 has 
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previously been described in the cellular nuclear fraction as a transcriptional 
regulator of the spermatid-specifc SP-10 gene [78]. Therefore, TDP-43 
redistribution in our study may represent an important mechanism of increased 
transcriptional regulation by TDP-43 during stress.  
TDP-43 is also an important splicing regulator. Alternative splicing is a 
key mechanism during an insult, allowing the production of protein isoforms 
that enable the cell to better manage the stress and favour the repair of the 
damage caused [156]. Sam68, another RBP, also associates with insoluble 
chromatin and nuclear matrix fractions under stress [156]. Specifically, 
genotoxic stress induces redistribution of chromatin components with an 
enrichment of Sam68 and hnRNP A1 in transcriptionally active fractions. The 
subnuclear re-localization of Sam68 correlates with changes in alternative 
splicing of its mRNA targets. Therefore, during stress, TDP-43 may also play a 
role in specific splicing events, similar to other splicing regulators including 
TIA-1 and hnRNP A1, which show the same redistribution with stress [156]. 
Furthermore, Sam68 localizes to cytoplasmic SGs with genotoxic and oxidative 
stress, and interacts with both TIA-1 and G3BP in order to be recruited to SGs 
[156, 157]. An increase in the insoluble fraction of stress proteins, like TIA-1, 
during an insult is consistent with the formation of SGs. Therefore, TDP-43 
redistribution to an insoluble fraction likely reflects its localization to cytosolic 
SGs during stress. Such localization may indicate cytoplasmic functions such as 
mRNA silencing, trafficking, storage, and sorting. Future studies are required to 
determine whether redistribution also involves stress-specific nuclear functions 
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such as transcription and splicing. 
In our study, TDP-43 does not localize to PBs, which are sites of mRNA 
degradation, but is found to be in close proximity. Although TDP-43 does not 
directly localize to PBs, it may still be functionally associated. For example, 
TDP-43 could be involved in the tethering of SGs to PBs or could determine 
the fate of transcripts that arrive at SGs (e.g. storage or degradation). Indeed, 
hnRNP D demonstrates such a role, promoting decay during oxidative stress 
[13]. In response to prostaglandin A2, an oxidative stressor, hnRNP D lowers 
the stability of cyclin D1 mRNA, targeting it for decay. Although the 
mechanisms of degradation are not well understood, both the exosome and PBs 
are involved. Interestingly, TDP-43 co-localizes with SGs and PBs in ALS 
spinal cord motor neurons, which is consistent with the re-localization of TDP-
43 under neuronal stress [93]. Therefore, we speculate TDP-43 does play a role 
in mRNA degradation during stress, albeit secondary. 
hnRNP A2 localizes to SGs with oxidative stress 
For the first time, we show endogenous hnRNP A2 forms cytoplasmic 
puncta in response to oxidative stress and these puncta localize to the same SGs 
as TDP-43. hnRNP A2 directly interacts with TDP-43, although functional 
links remain to be established [85]. hnRNP A2 is a nuclear-cytoplasmic 
shuttling protein with known functions is RNA processing and trafficking, 
telomere maintenance and oncogenesis [46, 158-161]. More recently, hnRNP 
A2 was described as a transcriptional co-activator of stress responsive genes in 
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the mitochondrial respiratory response pathway [162]. There are currently no 
reports that suggest a role for hnRNP A2 in the cellular stress response 
however, hnRNP A2 also directly interacts with PAPB1, which is a well-known 
SG component [26, 163]. Defining the role of hnRNP A2 during cellular stress 
remains to be investigated. 
TDP-43 Regulates Stress Granule Dynamics 
 Our study demonstrates a novel role for TDP-43 in SG dynamics. SG 
formation is a transient event in which a cellular insult causes nuclear TIA-1 to 
translocate to the cytosol followed by the subsequent aggregation into SGs. The 
process occurs over approximately 15 minutes and once the insult is removed, 
SGs continue to coalesce for up to one hour [27]. SGs become larger and fewer 
over time, until eventually disassembling as the cell recovers. We show that 
TDP-43 depleted cells fail to form morphologically distinct SGs where SGs are 
fewer and smaller. Additionally, SGs in TDP-43 reduced cells are unable to 
persist for the same period as control. Therefore, although small SGs do form, 
and eventually attain a similar size and morphology as control, the structure 
dissipates quickly. These results indicate that TDP-43 is required for the proper 
formation and maintenance of SGs. Some SG-associated proteins serve as 
molecular scaffolds that define the SG domain. Indeed, fas-activated 
serine/threonine phosphoprotein, a TIA-1 binding protein, nucleates PBs and 
SGs and is stably associated with both [35]. While most SG proteins constantly 
shuttle through SGs, arguing against a rigid SG structural compartment, the 
composition of SGs remains relatively constant [29, 32, 35]. TDP-43 has 
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structural characteristics that support a role in SG formation. For example, 
G3BP, a key factor in SG assembly has a dimerization domain that contributes 
to SG formation during arsenite treatment [21]. TDP-43 also has the capacity to 
dimerize [164]. Dimerization has been demonstrated by immunoprecipitation in 
which endogenous full-length TDP-43 and an exogenous flag-tagged protein 
interact via the N-terminus [164]. When the 86kDa dimerized protein is over-
expressed in cells, it is sequestered in the cytoplasm and promotes the 
accumulation of TDP-43 immunoreactive proteins. Additionally, TDP-43 itself 
is inherently aggregate prone and contains a region (amino acids 343–360) rich 
in the amino acids glycine, glutamine and/or asparagine [28]. This type of 
sequence also exists in the PRD of TIA1-1, and has been shown to form 
specific aggregates that mediate the assembly of SGs. Therefore, TDP-43 may 
have a domain that is required for SG structure/assembly or mediates an 
interaction with SG components for proper aggregation. As such, Colombrita 
and colleagues have found that the selective lack of 100 amino acids in the C-
terminal region of TDP-43, responsible for protein-protein interactions, results 
in the failure of TDP-43 to assemble into SGs [94]. Interestingly, the 
aggregation-prone domains of one protein can interact with other proteins to 
influence the transition between soluble and aggregation-prone confirmations 
[28]. In agreement with this, we show that TDP-43 regulates TIA-1 
distribution.  
TDP-43 regulation of TIA-1 and G3BP 
 The soluble form of TIA-1 acts as a translational silencer and the 
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insoluble aggregated form promotes stress-induced translational arrest via SG 
assembly. Therefore, TIA-1 solubility is critical for SG assembly. The exact 
mechanisms governing TIA-1 solubility are not well understood however, there 
is evidence suggesting HSP70 regulation is involved [28]. Gilks and colleagues 
have shown that HSP70 is required to maintain TIA-1 in a soluble (nuclear) 
form [28]. Therefore, during an insult, as HSP70 is recruited for protein 
renaturing, it is diverted from TIA-1, leading to TIA-1 aggregation and 
subsequent SG nucleation. Once the stress is removed, HSP70 once again 
solubilizes TIA-1, promoting SG disassembly. In TDP-43 depleted cells, we 
show an increase in the accumulation of soluble TIA-1 protein and an increase 
in mRNA with a concurrent decrease in insoluble TIA-1. TDP-43 regulation of 
TIA-1 provides a mechanism for impaired SG formation such that TIA-1 is 
hindered in transitioning to an insoluble form, thus delaying its aggregation into 
SGs. Therefore, we propose that TDP-43 is required for the initial homotypic 
aggregation of TIA-1, if not the heterotypic aggregation as well. However, SGs 
eventually attain a similar morphology and size as controls, suggesting that 
TIA-1, and perhaps other proteins, may be able to compensate or overcome 
TDP-43 deficits.  
 TDP-43 regulation of TIA-1 is also of particular interest since factors that 
regulate TIA-1 aggregation may influence cell survival. Normally TIA-1 
aggregation is reversible, however when damage exceeds cellular thresholds, 
the aggregation is irreversible [27]. Thus, one could hypothesize that in an ALS 
disease context, the presence of TDP-43 mutants could enhance TIA-1 
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deregulation, contributing to a maladaptive stress response. Over time, this 
deregulation could lead to SGs that no longer dispersed, forming the initial 
pathological aggregates. In our model, we present an acute model of stress, 
whereas the disease context more likely represents chronic stress. Therefore, 
future studies will be aimed at investigating the role of TDP-43 in the CSR with 
chronic stress.  
 We also show that endogenous TDP-43 regulates SG dynamics via G3BP 
regulation. In TDP-43 depleted cells, there is a decrease in G3BP at both the 
mRNA and protein level. SG formation is inhibited in cells that are deficient in 
G3BP [31]. Therefore, TDP-43 induced reduction of G3BP is consistent with 
diminished SG assembly, providing a second mechanism for impaired SG 
dynamics. Interestingly, other studies have shown that TDP-43 functions as an 
mRNA stabilizing factor [75, 86]. Thus, TDP-43 may be required for the 
stabilization of G3BP mRNA, if not other mRNAs of SG components. 
Therefore, our evidence places TDP-43 upstream in the CSR in the regulation 
of SG components. Of note, eIF2! phosphorylation levels remain unchanged 
with TDP-43 depletion thus placing TDP-43 downstream of eIF2! 
phosphorylation. Furthermore, we suggest there is an interaction between TDP-
43 and SG components that is crucial for proper SG formation. Consistently, 
we show both G3BP and hnRNP A2 fail to form discrete puncta in TDP-43 
depleted cells. Both proteins have altered morphologies and distributions (e.g. 
more diffuse) within the cytosol following oxidative stress. Detailed studies 
examining other SG factors will provide insight as to whether this effect is a 
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specific effect of TDP-43 on hnRNP A2 and G3BP, or a global effect of TDP-
43 on SGs, such that no SG components are able to aggregate properly. 
Moreover, determining whether ALS-linked mutations in TDP-43 affect TDP-
43 regulation of SG proteins is an interesting next step. 
hnRNP A2 redistribution  
 Our study demonstrates that TDP-43 regulates hnRNP A2 distribution. In 
cells depleted of TDP-43, hnRNP A2 redistributes from a soluble to an 
insoluble form. It is not uncommon for hnRNP proteins to interact and 
collaborate in order to carry out specific functions. Indeed, hnRNP A1 and 
hnRNP H interact directly to enforce specific splicing decisions, providing an 
important mechanism of splicing control [165]. Moreover, several hnRNP 
related molecules can replace each other, particularly in the case of the hnRNP 
A/B family, to carry out functions such as alternative splicing. For instance, 
hnRNP A1 is involved in mouse hepatitis virus replication and transcription 
[59]. In the absence of hnRNP A1, mouse hepatitis virus RNA interacts with 
several alternate proteins, all belonging to the hnRNP A/B family in RNA 
replication. This event is attributed to the structural similarities between these 
proteins, particularly the homology of their RBDs. Further evidence for this 
phenomenon is demonstrated in the mouse erythroleukemia cell line CB3 
which is an hnRNP A1-deficient cell line. The deletion is not lethal, suggesting 
critical hnRNP A1 functions are replaced by other alternative factors [166]. 
TDP-43 is most closely related to the hnRNP A/B family and directly interacts 
with hnRNP A2. Therefore, hnRNP A2 redistribution with TDP-43 depletion 
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may represent a compensatory mechanism where hnRNP A2 replaces, and 
carries out, the functions of TDP-43 in its absence.  
TDP-43 mutations 
 Our results provide evidence for impaired SG formation in human patient 
lymphoblastoid cells expressing the disease-causing mutation TDP-43
R361S
. 
This observation is not the result of decreased protein expression since we show 
both TDP-43
D169G
 and TDP-43
R361S
 have increased steady-state expression 
levels. An increase in mutant TDP-43 protein levels is not surprising, 
considering that TDP-43 mutants have increased protein stability [167]. The 
defect conferred by the TDP-43
R361S
 mutation provides an interesting new 
avenue to explore involving HDAC6. HDAC6, a multifunctional deacetylase 
that plays a role in deciding the fate of polyubiquitinated proteins, is also a 
component of SGs and is required for SG assembly [160, 170]. In cells lacking 
HDAC6, TIA-1 remains largely nuclear, failing to translocate to the cytoplasm 
[170]. Moreover, HDAC6 deficient mouse embryonic fibroblasts fail to form 
morphologically discrete SGs. Fiesel and colleagues have shown, in a cell 
culture model, that TDP-43 regulates HDAC6 levels such that silencing of 
TDP-43 results in specific down-regulation of HDAC6 (both at the protein and 
mRNA level) [168]. Moreover, the expression of various TDP-43 mutants is 
able to restore HDAC6 levels to control levels, except expression of the R361S 
mutant. Therefore, given these data, the TDP-43
R361S
 mutation may be hindered 
in its ability to form SGs in our study due to deregulation of HDAC6.  
 More recently, TDP-43 has been shown to form a complex with FUS/TLS 
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to coregulate HDAC6 [86]. Therefore, mutations in either TDP-43, or 
FUS/TLS, may result in a dysfunctional complex, deregulating its target 
mRNA, and thus impairing SG formation. As such, it would be interesting to 
investigate whether the TDP-43:FUS/TLS complex is important in the 
regulation of other components of the stress response, such as TIA-1 or G3BP. 
The relationship between TDP-43, FUS/TLS, HDAC6 and SGs requires further 
investigation. Future studies are also required to properly understand how 
different ALS-linked mutants may perturb the normal stress response and 
components of the pathway.  
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E. CONCLSUION 
 Cellular recovery from stress is not successful when damage exceeds 
certain thresholds, or when one or more components of the stress-activated 
cascade is impaired. The SG pathway is increasingly implicated in disease. For 
example, it has been demonstrated that SMN, a protein associated with 
autosomal recessive motor neuron disease and spinal muscular atrophy, 
facilitates SG formation and may influence neurodegeneration via the 
disruption of RNA stability through SG function [152]. Furthermore, in 
Parkinson’s disease it is proposed that large pathological aggregates arise due to 
disrupted SG dynamics [169]. Taken together, our data demonstrate an 
important role for TDP-43 in response to acute cellular stress. During an insult, 
we propose that TDP-43 may function in stress-specific splicing and 
transcription, ultimately influencing gene regulation and cellular survival. We 
provide evidence for TDP-43 localization to SGs with various types of insults 
and show TDP-43 is not merely a resident of SGs, but participates in the stress 
response. TDP-43 functions as an integral component in SG assembly and an 
upstream regulator of key SG proteins. Furthermore, we provide the first 
description of hnRNP A2 in the CSR, localized t SGs, and we hypothesize that 
hnRNP A2 may compensate for TDP-43 when TDP-43 is silenced. One 
method, in the context of this study, to test this hypothesis is to determine if the 
expression of hnRNP A2 could restore defects in both SG dynamics and TIA-
1/G3BP levels in the absence of TDP-43. Confirming this hypothesis presents 
an interesting mechanism of how to overcome deficits resulting from TDP-43 
  
 
 93  
mutations. 
We describe an effect for one TDP-43 mutation, which is deficient in 
the formation of SGs. The effects of TDP-43 mutations on its proper 
functioning in the CSR can be numerous. For instance, mutations representing a 
loss or gain of function can range from incomplete repression of mRNAs or de-
repression at inappropriate timing, defects in splicing and transcription, 
alterations in cell stress signaling pathways and also changes in the regulation 
of gene transcription.  
In conclusion, our study provides a model for how TDP-43, as a key 
player in the CSR, can contribute to disease. Disruptions of TDP-43 lead to 
impairments in the stress response via different mechanisms. Two of which are 
TIA-1 and G3BP regulation, essentially resulting in improper SG formation and 
maintenance (Fig 1). We believe a muted stress response over time, paired with 
successive encounters of oxidative stress, may lead to an overall inefficiency of 
cells to manage and recover from stress, ultimately leading to death. Defining 
the relevance of this study of TDP-43 biology specifically in motor neurons and 
ALS is now an ensuing challenge. 
TDP-43
siRNA or mutation
TIA-1
aggregation
G3BP
transcription
Slowed SG maturation
Diminished SG maintenance
Enhanced sensitivity to environmental stress
?
Motor neuron vulnerability & death
?
Figure 1. Model of TDP-43 in regulation of SGs. (Figure 
adapted from McDonald, K.K., Aulaus, A., et al. (2010). 
Manuscript under revision) 
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APPENDIX  
I. Results Omitted from Manuscript 
Figure 1. Endogenous TDP-43 regulates hnRNP A2 solubility 
Given our data that TDP-43 regulates SG components, both hnRNP A2 
and TDP-43 localize to SGs, and that TDP-43 and hnRNP A2 are reported to 
directly interact [85], we hypothesized that TDP-43 may regulate hnRNP A2 
directly. Using TDP-43 siRNA, we established conditions which consistently 
yield an average 84% reduction of TDP-43 protein levels compared to control 
siRNA 72 hours post-transfection (Fig. 1A). Interestingly, the pool of soluble 
hnRNP A2 was also found to be reduced 56% in TDP-43 depleted cells 
suggesting that TDP-43 directly regulates hnRNP A2 (Fig. 1A). hnRNP 
proteins commonly exist in RIPA-soluble and insoluble compartments, likely 
due to their ability to form large ribonucleoprotein complexes and/or interact 
with nuclear matrix components. Thus, we sought to determine whether the 
apparent reduction in hnRNP A2 was due to TDP-43 regulation of hnRNP A2 
distribution in RIPA solubilized cells. We noted that in control siRNA cells, 
45% of total hnRNP A2 is soluble (Fig. 1B). However, in the absence of TDP-
43 there is a two-fold decrease in the available soluble pool of hnRNP A2 and a 
concomitant increase in hnRNP A2 in the insoluble fraction of RIPA-
solubilized cells such that 77% of hnRNP A2 is insoluble (Fig. 1B). The impact 
of TDP-43 on hnRNP A2 distribution was specific since the distribution of the 
related molecule hnRNP A1 was unchanged in the absence of TDP-43. Thus, 
TDP-43 is required to maintain a soluble pool of hnRNP A2.
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